Florida International University

FIU Digital Commons
FIU Electronic Theses and Dissertations

University Graduate School

6-24-2020

Predictors of Persistent and Recurrent Bacterial Vaginosis (BV)
among Young African American (AA) women in the United States
Makella S. Coudray
Florida International Univeristy, mcoud001@fiu.edu

Follow this and additional works at: https://digitalcommons.fiu.edu/etd
Part of the Clinical Epidemiology Commons, Epidemiology Commons, and the Women's Health
Commons

Recommended Citation
Coudray, Makella S., "Predictors of Persistent and Recurrent Bacterial Vaginosis (BV) among Young
African American (AA) women in the United States" (2020). FIU Electronic Theses and Dissertations.
4511.
https://digitalcommons.fiu.edu/etd/4511

This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It
has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU
Digital Commons. For more information, please contact dcc@fiu.edu.

FLORIDA INTERNATIONAL UNIVERSITY
Miami, Florida

PREDICTORS OF PERSISTENT AND RECURRENT BACTERIAL VAGINOSIS
(BV) AMONG YOUNG AFRICAN AMERICAN (AA) WOMEN IN THE UNITED
STATES (US)

A dissertation submitted in partial fulfillment of
the requirements for the degree of
DOCTOR OF PHILOSOPHY
in
PUBLIC HEALTH
by
Makella Shaniece Coudray
2020

To: Dean Tomás R. Guilarte
Robert Stempel College of Public Health and Social Work
This dissertation, written by Makella Shaniece Coudray, and entitled Predictors of
Persistent and Recurrent Bacterial Vaginosis (BV) among Young African American (AA)
Women in the United States (US), having been approved in respect to style and
intellectual content, is referred to you for judgment.
We have read this dissertation and recommend that it be approved.

_______________________________________
Diana Sheehan
_______________________________________
Tan Li
_______________________________________
Giri Narasimhan
_______________________________________
Purnima Madhivanan, Major Professor
Date of Defense: June 24, 2020
The dissertation of Makella Shaniece Coudray is approved.

_______________________________________
Dean Tomás R. Guilarte
Robert Stempel College of Public Health and Social Work

_______________________________________
Andrés G. Gil
Vice President for Research and Economic Development
and Dean of the University Graduate School

Florida International University, 2020

ii

© Copyright 2020 by Makella Shaniece Coudray
All rights reserved.

iii

DEDICATION
This dissertation is dedicated to my parents. Without their patience, understanding,
support, and most of all love, the completion of this work would not have been possible.
They are the pillars of my success.

iv

ACKNOWLEDGMENTS
I wish to thank the members of my committee for their support and patience.
Their knowledge and guidance have been most appreciated. Drs. Diana Sheehan and Tan
Li were particularly helpful in guiding me through my methodology and statistical
analyses. I remain forever grateful for their open doors and listening ears, even for the
most trivial of questions. Dr. Giri Narasimhan’s expertise allowed me to explore
additional areas of my research. Finally, I would like to thank my major professor, Dr.
Purnima Madhivanan. From the beginning, she had confidence in my abilities to not only
complete my degree, but to complete it with excellence. Her continued and unwavering
support has been instrumental in the completion of my dissertation.
I would also like to thank my family. Their silent prayers, well wishes and
tremendous support have allowed me to successfully complete this work. I would be
remiss to neglect the friends I acquired during this process who in turn provided me with
balance and comfort in times of need. Their contribution to my success remains
invaluable.
Finally, this work was supported by the National Institutes of Health grant
(R15AI28714-01) and by the Division of Microbiology and Infectious Diseases of the
NIAID (contract HHSN26620040073C). The content is solely the responsibility of the
authors and does not necessarily represent the official views of the National Institutes of
Health.

v

ABSTRACT OF THE DISSERTATION
PREDICTORS OF PERSISTENT AND RECURRENT BACTERIAL VAGINOSIS
(BV) AMONG YOUNG AFRICAN AMERICAN (AA) WOMEN IN THE UNITED
STATES (US)
by
Makella Shaniece Coudray
Florida International University, 2020
Miami, Florida
Professor Purnima Madhivanan, Major Professor
Bacterial vaginosis (BV) is a common vaginal dysbiosis among women of
reproductive age. Literature presents discordant findings with respect to the predictors of
BV and there is a paucity of literature examining the mechanisms by which multiple
episodes of BV occur. This dissertation summarized current literature on BV, identified
BV incidence patterns over a twelve-month period, and estimated the risk of sexually
transmitted infections (STI) among women with episodic and persistent BV. Previously
collected randomized clinical trial data were analyzed, where oral metronidazole was the
administered treatment. Latent class analysis (LCA) was used to assess BV incidence
patterns. Multinomial Logistic Regression was used to estimate adjusted Odds Ratios
(adjOR) associated with the predictors of BV incidence patterns. Binary Logistic
Regression models were used to estimate adjOR associated with STI acquisition among
women with persistent BV compared to episodic BV.
The results of the review identified conflicts in the literature further highlighted
what little is known about the etiology and pathogenesis of BV, recurrent BV and
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persistent BV. LCA illustrated three emergent patterns of multiple cases of BV: persistent
(55.9%; 95 % Confidence Interval [CI]: 52.5%-59.3%), recurrent (30.5%; 95% CI:
27.5%-33.7%) and clearance (13.5%; 95% CI:1.3%-16.0%). Compared with belonging to
the clearance group, women who had sex with women (WSW) had significantly lower
odds of belonging to the persistent class (adjOR: 0.38; 95% CI: 0.22-0.68) and the
recurrent class (adjOR: 0.43; 95% CI: 0.23-0.81) than women who did not. Those who
were treated with metronidazole had significantly increased odds of being in the recurrent
class (adjOR: 1.92; 95% CI: 1.22-3.03) than those who were not treated. Additionally,
women with persistent and episodic BV were at increased risk (p= 0.02) of developing an
STI. Women without BV did not acquire an STI.
Assessment of BV cases revealed distinct patterns of recurrence and persistence
despite treatment with oral metronidazole. These preliminary findings suggest,
Metronidazole may not be the most effective treatment to reduce the prevalence of
recurrent and persistent cases of BV. More effective treatment of singular episodes of BV
may reduce the adverse sequalae of incident STI, we reported associated with recurrent,
episodic and persistent BV. The review identified gaps in the literature, which were
addressed by the second and third aims.

vii

TABLE OF CONTENTS
CHAPTER

PAGE

INTRODUCTION .............................................................................................................. 1
MANUSCRIPT 1 ................................................................................................................ 6
Abstract ........................................................................................................................... 6
Introduction ..................................................................................................................... 7
Epidemiology of BV ....................................................................................................... 9
Diagnosis and Treatment of BV .................................................................................... 11
Recurrent and Persistent BV ......................................................................................... 14
Predisposing Factors associated with BV ..................................................................... 16
The Vaginal Microbiota and BV ................................................................................... 22
BV and Adverse Sequalae ............................................................................................. 23
References ..................................................................................................................... 26
MANUSCRIPT 2 .............................................................................................................. 35
Abstract ......................................................................................................................... 35
Introduction ................................................................................................................... 36
Materials and Methods .................................................................................................. 38
Results ........................................................................................................................... 42
Discussion ..................................................................................................................... 45
References ..................................................................................................................... 50
Tables ............................................................................................................................ 54
MANUSCRIPT 3 .............................................................................................................. 62
Abstract ......................................................................................................................... 62
Introduction ................................................................................................................... 63
Methods ......................................................................................................................... 65
Results ........................................................................................................................... 68
Discussion ..................................................................................................................... 71
References ..................................................................................................................... 73
Tables ............................................................................................................................ 76
CONCLUSIONS............................................................................................................... 81
VITA ................................................................................................................................. 83

viii

LIST OF TABLES
TABLE

PAGE

MANUSCRIPT 2
Table 1: Participant Characteristics stratified by Latent Class…………………………..54
Table 2: Crude and Adjusted Odds Ratios for Risk Factors Associated with Latent
Class by Multinomial Logistic Regression Analysis…………………………………….58
MANUSCRIPT 3
Table 1: Characteristics associated with incident STI Infection after eight months……..76
Table 2: Factors Associated with BV Status……………………………………………..78
Table 3: Factors Associated with Sexually Transmitted Infection Diagnosis among
Participants ………………………………………………………………………………80

ix

ABBREVIATIONS AND ACRONYMS
adjOR

Adjusted Odds Ratio

BV

Bacterial Vaginosis

CI

Confidence Interval

CT

Chlamydia Trachomatis

HR

Hazard Ratio

IUD

Intra-Uterine Device

LCA

Latent Class Analysis

NG

Neisseria Gonorrhoeae

NS

Nugent Score

OR

Odds Ratio

US

United States

x

INTRODUCTION
Bacterial Vaginosis (BV) is the most common cause of abnormal vaginal
discharge.(Bradshaw et al., 2006; Koumans et al., 2007; Hay, 2014) BV is characterized
by an imbalance in vaginal microflora where there is overgrowth of naturally occurring
bacteria such as Gardnerella vaginalis and Mycoplasma hominis and a decrease in levels
of Lactobacilli.(Bradshaw et al., 2006; Koumans et al., 2007; Hay, 2014; Lambert, John,
Sobel, & Akins, 2013; J. Wilson, 2004) BV is the most common vaginal infection among
women of reproductive age (Guédou et al., 2013) that affects approximately 29% of
women in the United States (US) compared to 12% of Australian women and more than
50% of women in Eastern/Southern Africa.(Bradshaw & Sobel, 2016; Chen, Tian, &
Beigi, 2009; Koumans et al., 2007; Jung, Ehlers, Lombaard, Redelinghuys, & Kock,
2017; Madden, Grentzer, Secura, Allsworth, & Peipert, 2012; J. Wilson, 2004)
Approximately 50% of women with BV are asymptomatic.(Koumans et al., 2007; Hay,
2014) BV can increase the risk of contracting many sexually transmitted infections (STIs)
(Muzny, Sunesara, Austin, Mena, & Schwebke, 2013) such as human immunodeficiency
virus (HIV), Neisseria gonorrhea (NG), Chlamydia trachomatis (CT), Trichomonas
vaginalis (TV) and Herpes simplex virus-2 (HSV-2).(Bradshaw & Sobel, 2016;
Bradshaw et al., 2006; Chen et al., 2009; Koumans et al., 2007; Hay, 2014; Jung et al.,
2017; Machado, Castro, Palmeira-de-Oliveira, Martinez-de-Oliveira, & Cerca, 2015;
Madden et al., 2012; Payne, Cromer, Stanek, & Palmer, 2010; Sobel et al., 2006) HIV
infected women with BV experience increased viral shedding.(Koumans et al., 2007;
Madden et al., 2012) This may be a result of specific bacteria associated with BV that
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induce viral replication and shedding. Increased viral shedding may lead to increased
HIV transmission.(Wessman et al., 2017) Additionally, BV is associated with adverse
reproductive health outcomes such as spontaneous abortion, low birth weight, pelvic
inflammatory disease and gynecologic post-operative infections.(Bradshaw & Sobel,
2016; Chen et al., 2009; Machado et al., 2015; Madden et al., 2012; Payne et al., 2010;
Sobel et al., 2006) BV associated sequelae also impact health care expenditure. For
example, the population attributable risk of BV for preterm delivery in the US was
previously estimated to be 30%, incurring a cost of approximately one billion US dollars
annually. (Bradshaw & Sobel, 2016)
The etiology and pathogenesis of BV are still not completely clear leading to high
recurrence rates despite treatment.(Bradshaw & Sobel, 2016; Bradshaw & Brotman,
2015; Cook, Redondo-Lopez, Schmitt, Meriwether, & Sobel, 1992; Guédou et al., 2013;
Lambert et al., 2013; Machado et al., 2015; Madden et al., 2012; Marshall, 2015; Menard,
2011; Payne et al., 2010; Schwebke, Richey, & Weiss2, 1999; Sobel et al., 2006; J. D.
Wilson et al., 2005) There is a 15-30% recurrence rate of BV within three months of
completing treatment.(Bradshaw & Sobel, 2016; Bradshaw et al., 2006; Cook et al.,
1992; J. Wilson, 2004) Recurrent BV can be described as women having three or more
confirmed episodes of BV within twelve months.(J. Wilson, 2004) BV persists in
instances where recommended treatment methods are not effective, or lactobacilli levels
fail to recolonize to normal levels.(Bradshaw & Sobel, 2016) Long term cure rates, 6-12
months, of BV treatment are approximately 50%.(Bradshaw & Sobel, 2016) It is unclear
whether these high failure rates are due to failure of the treatment to eradicate the
causative agents or failure of the women to re-establish a Lactobacilli dominant vaginal
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microbiota. Women with recurrent BV experience periods where they are completely
cured of BV and are later diagnosed with BV, whereas women with persistent BV are not
cured. Distinguishing between BV persistence and recurrence could help to determine the
possible causes of high failure rates for BV treatment.
The overall objective of this dissertation was to examine the factors associated
with recurrent and persistent BV among young African American women of reproductive
age. The first study aimed to summarize current literature on the epidemiology of BV and
highlight areas of deficiency in current clinical practice with respect to BV. The second
study aimed to identified BV incidence patterns over a twelve-month period and
evaluated the demographic and behavioral risk factors associated with these patterns. The
third study examined whether women with persistent BV were more likely to acquire a
CT/NG infection compared to women with episodic BV in a population of African
American women.
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MANUSCRIPT 1
© Copyright 2020
Coudray MS, Madhivanan P. Bacterial Vaginosis - A Brief Synopsis of the Literature.
European Journal of Obstetrics & Gynecology and Reproductive Biology. 2020;
245:143-148.
Abstract
Background: Bacterial vaginosis (BV) affects women of reproductive age and can either
be symptomatic or asymptomatic. Approximately 50% of women are symptomatic and
experience vaginal malodor, discharge, itching and increased vaginal pH. BV can
increase the risk of contracting many sexually transmitted infections (STIs) such as
human immunodeficiency virus (HIV), Neisseria gonorrhea (NG), Chlamydia
trachomatis (CT), Trichomonas vaginalis (TV) and herpes simplex virus-2 (HSV-2).
Though effective treatment options do exist, metronidazole or clindamycin, these
methods have proven not to be effective long term. Objective: The purpose of this
review is to summarize current literature on the epidemiology of BV and highlight areas
of deficiency in current clinical practice with respect to BV. Results: BV recurrence rates
are high, approximately 80% three months after effective treatment. Furthermore, in
some instances treatment is ineffective and BV persists. Literature also documents the
relationship between BV and human papillomavirus (HPV). HPV is the most common
sexually transmitted infection among young adult women while BV is the most common
cause of vaginal symptoms among women of reproductive age. BV is associated with
high levels of anaerobic organisms which can damage the vaginal epithelium and
increase the risk of HPV infection. Recent research also highlights the role of the vaginal
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microbiome in BV. Conclusion: The results of this review warrant further exploration
into the etiology of BV as well as exploration of more long-term effective treatment and
the investigation of prognostic indicators. Additionally, the need for a standard definition
of recurrent and persistent BV is recognized.
Keywords: Bacterial vaginosis, treatment, vaginal microbiome, sexually transmitted
infections
Introduction
Bacterial Vaginosis (BV) is a common vaginal dysbiosis among women of
reproductive age.(Bautista, Wurapa, Sateren, et al., 2016; Morris, Rogers, & Kinghorn,
2001; Ranjit, Raghubanshi, Maskey, & Parajuli, 2018; Schwebke & R. Desmond, 2007a)
Gardner and Dukes first described BV in 1955.(Bautista, Wurapa, Sateren, et al., 2016;
Gardner & Dukes, 1955; Menard, 2011) The syndrome was initially termed
“Haemophilus vaginalis vaginitis,” based on the organism that was previously believed to
be the etiologic agent, H. vaginalis.(Bautista, Wurapa, Sateren, et al., 2016; Gardner &
Dukes, 1955; Morris et al., 2001) It was later discovered that H. vaginalis did not belong
to the genus Haemophilus and the bacteria was renamed Gardnerella vaginalis.(Bautista,
Wurapa, Sateren, et al., 2016) BV was also called nonspecific vaginitis and Gardnerella
vaginalis vaginitis.(Gibbs, 2007; Hay, 2014; Holzman et al., 2001) Currently, the
etiology of BV is unknown.(Bautista, Wurapa, Sateren, et al., 2016; Bautista, Wurapa, &
Sanchez, 2016; Bradshaw et al., 2006; Fethers et al., 2009; Guedou et al., 2013; Hay,
2014; Joesoef & Schmid, 1995; Kenyon, Colebunders, & Crucitti, 2013; Klatt, Cole,
Eastwood, & Barnabei, 2010; Lambert, John, Sobel, & Akins, 2013; Muzny, Sunesara,
Austin, Mena, & Schwebke, 2013; Schwebke, 2000; J. R. Schwebke & R. Desmond,
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2007a; Schwebke, Richey, & Weiss, 1999; Wilson, 2004) However, it has been
determined that BV is characterized by overgrowth of opportunistic bacteria and a
decrease in the levels of Lactobacilli.(Bradshaw et al., 2006; Bradshaw & Sobel, 2016;
Hay, 2014; Holzman et al., 2001; Klatt et al., 2010; Madden, Grentzer, Secura,
Allsworth, & Peipert, 2012; Muzny et al., 2013; Ranjit et al., 2018; Schwebke &
Desmond, 2007b; Schwebke et al., 1999; Wilson, 2004) A healthy vaginal flora is
dominated by Lactobacilli,(Bautista, Wurapa, Sateren, et al., 2016; Bautista, Wurapa, &
Sanchez, 2016; Hay, 2014; Klatt et al., 2010; Lambert et al., 2013; Madden et al., 2012;
Marshall, 2015; Schwebke et al., 1999) approximately 90-95% of total bacteria.(Bautista,
Wurapa, Sateren, et al., 2016; Japanese Society of Chemotherapy Committee on
guidelines for treatment of anaerobic & Japanese Association for Anaerobic Infection,
2011) However, research also indicates that some healthy women do not possess a
Lactobacillus-dominated vaginal microbiota.(Ravel et al., 2011; Smith & Ravel, 2017;
Zhou et al., 2004) In cases of BV, mainly anaerobic microorganisms such as grampositive cocci and gram-negative bacilli dominate the vaginal flora.(Cook, RedondoLopez, Schmitt, Meriwether, & Sobel, 1992) Common opportunistic bacteria include
Prevotella species, Gardnerella vaginalis and Mobiluncus species.(Bautista, Wurapa,
Sateren, et al., 2016; Holzman et al., 2001; Joesoef & Schmid, 1995; Lambert et al.,
2013; Madden et al., 2012; Marshall, 2015; Mohammadzadeh, Dolatian, Jorjani, & Alavi
Majd, 2014; Muzny et al., 2013; Schwebke, 2000; Wilson, 2004)
BV is the most common cause of abnormal vaginal discharge.(Bautista, Wurapa,
Sateren, et al., 2016; Bradshaw et al., 2006; Hay, 2014; Muzny et al., 2013) Symptomatic
BV is also characterized by vaginal malodor, increased vaginal pH and vaginal
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itching.(Bradshaw & Sobel, 2016; Hay, 2014; Joesoef & Schmid, 1995; Klatt et al., 2010;
Menard, 2011; Schwebke, 2000; Schwebke & Desmond, 2007a) There has been
approximately 65 years of research conducted on BV. After over six decades, researchers
have still been unable to elucidate the causative agent of BV and issues of adverse BVassociated sequelae are very poorly understood, further emphasizing the clinical
conundrum that is BV. This review presents a brief summary of the major research
findings with respect to the epidemiology of BV, recurrence and persistence of BV,
known correlates of BV and the effect of BV on the vaginal microbiota.

Epidemiology of BV
The prevalence of BV varies internationally and intranationally.(Bautista,
Wurapa, Sateren, et al., 2016; Kenyon et al., 2013) The prevalence of BV can range from
20-60% from country to country.(Bautista, Wurapa, Sateren, et al., 2016) BV prevalence
is highest in Sub-Saharan Africa.(Bautista, Wurapa, Sateren, et al., 2016; Kenyon et al.,
2013) The prevalence of BV is higher in South East Africa when compared to West
Africa.(Bautista, Wurapa, Sateren, et al., 2016; Kenyon et al., 2013) A study conducted
by Myer et al. in South Africa reported that the prevalence of BV was 58.3% as of
2002.(Kenyon et al., 2013; Myer et al., 2005) Additionally, in the year 2000, reported BV
prevalence in Zimbabwe was 30.3%.(Kenyon et al., 2013; Kurewa et al., 2010) This can
be compared to Nigeria, where in 2005 the prevalence of BV was reported to be
14.2%.(Anukam, Osazuwa, Ahonkhai, & Reid, 2006; Kenyon et al., 2013) Prevalence of
BV is moderate in regions such as South and Southeast Asia, Latin America and the
Caribbean and the US.(Kenyon et al., 2013) In these regions the prevalence of BV was
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determined to be 23.2% in Bangladesh as of 2002,(Kenyon et al., 2013; Rahman et al.,
2008) 32% in Chile as of 2006(Kenyon et al., 2013; Villaseca et al., 2015) and 29.2% in
the US as of 2004.(Kenyon et al., 2013; Koumans et al., 2007; Mohammadzadeh et al.,
2014) Of note are regions such as Australia and New Zealand and Western Europe where
BV prevalence is the lowest.(Kenyon et al., 2013) The prevalence of BV in Australia was
determined to be 4.7% in 2008.(Fethers et al., 2009; Kenyon et al., 2013) Comparatively
low BV prevalence was also reported in Finland for the year 2008 as 8.6%.(Eriksson,
Adolfsson, Forsum, & Larsson, 2010; Gibbs, 2007; Kenyon et al., 2013) The
aforementioned countries used Nugent Scoring to evaluate the presence of BV.(Kenyon
et al., 2013)
Literature has not yet explored the predictors of intranational and international
differences with respect to the prevalence of BV. Cultural factors may play a role in the
in these observed differences. Additionally, there may be differences in surveillance
techniques used and BV may not be a reportable disease in every country. Diagnostic
techniques vary depending on the availability of resources. Approximately 50% of cases
of BV are asymptomatic.(Hay, 2014) Due to variations in clinical guidelines, BV may not
be screened for and the true prevalence of BV, within country, and reported prevalence
would not be the same. The US Preventive Services Task Force does not currently
recommend the screening of asymptomatic pregnant women for BV due to a lack of data
supporting the benefits of screening.(Guise, Mahon, Aickin, & Helfand, 2001; U.S.
Preventive Services Task Force, 2008) Furthermore, literature illustrates that there a lack
of studies which compare a screened and non-screened population.(Guise, Mahon,
Aickin, & Helfand, 2001; Guise, Mahon, Aickin, Helfand, et al., 2001) Similarly
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Canadian clinical guidelines only recommend BV screening for asymptomatic pregnant
women.(van Schalkwyk & Yudin, 2015) Our literature search did not highlight the
screening practices of other countries. It remains unclear why such a large percentage of
cases of BV are asymptomatic.(Schwebke, 2000) Longitudinal studies are needed to
assess the effect of screening for asymptomatic BV among pregnant and non-pregnant
women.

Diagnosis and Treatment of BV
BV is diagnosed using either Amsel’s criteria or Nugent score.(Allsworth &
Peipert, 2011; Hay, 2014; Madden et al., 2012; Marshall, 2015; Martin & Marrazzo,
2016; Menard, 2011; Mohammadzadeh et al., 2014; Schwebke, 2000) Amsel’s criteria is
more commonly used in clinical settings(Allsworth & Peipert, 2011; Rebecca M.
Brotman, 2011; Madden et al., 2012; Martin & Marrazzo, 2016; Menard, 2011) since it is
faster and more affordable than Nugent scoring.(Mohammadzadeh et al., 2014) Three of
the following Amsel’s criteria must be present to be diagnosed with BV; increased
homogeneous thin vaginal discharge, pH of the secretion greater than 4.5, amine odor
when potassium hydroxide 10% solution is added to a drop of vaginal secretions or
presence of clue cells in wet mount preparations.(Allsworth & Peipert, 2011; Bautista,
Wurapa, Sateren, et al., 2016; Klatt et al., 2010; Madden et al., 2012; Martin & Marrazzo,
2016; Menard, 2011; Mohammadzadeh et al., 2014) Gram stain techniques are utilized to
diagnose BV by Nugent scoring.(Bautista, Wurapa, Sateren, et al., 2016; Martin &
Marrazzo, 2016) Scoring is based upon the presence of different bacterial morphotypes
where a score ≥ 7 indicates the presence of BV, 4-6 intermediate and 0-3
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normal.(Bautista, Wurapa, Sateren, et al., 2016; Koumans et al., 2007; Madden et al.,
2012; Martin & Marrazzo, 2016; Menard, 2011; Spiegel, Amsel, & Holmes, 1983) Due
to the methodological differences between these two diagnostic techniques, this results in
varying degrees of accuracy when these methods are compared. However, once BV is
diagnosed it can be treated.
Treatment is only recommended for symptomatic women, according to the United
States (US) Centers for Disease Control and Prevention (CDC) treatment guidelines, due
to a lack of sufficient evidence to support treatment of asymptomatic women.(Koumans
et al., 2007; Workowski & Berman, 2010) The guidelines further indicate that there are
limited benefits of treatment in non-pregnant women and that treatment only provides
relief of symptoms.(Mark, Jordan, Cruz, & Warren, 2012) Thus women with
asymptomatic BV often experience high recurrence rates due to a lack of treatment. The
recommended forms of treatment for BV include metronidazole and
clindamycin.(Bradshaw et al., 2006; Bradshaw & Sobel, 2016; Cook et al., 1992;
Guaschino et al., 2003; Hay, 2014; Joesoef & Schmid, 1995) The aforementioned
antibiotics can be administered orally or intravaginally.(Chen, Tian, & Beigi, 2009;
Joesoef & Schmid, 1995) These recommended regimens have similar efficacy.(Bradshaw
& Sobel, 2016; Chen et al., 2009; Hay, 2014) Though treatment for BV is only
recommended for symptomatic cases of the disease,(J. R. Schwebke & R. Desmond,
2007b) literature suggests that treatment of asymptomatic BV may reduce the risk of BV
associated adverse sequelae.(Gibbs, 2007; Spiegel et al., 1983) Schwebke and Desmond
determined that treatment with intravaginal metronidazole gel significantly reduced the
risk of Chlamydia trachomatis (CT) infection.(J. R. Schwebke & R. Desmond, 2007b) In
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light of the studies which suggest that treatment of asymptomatic BV may reduce the risk
of acquisition of sexually transmitted infections (STIs) the current clinical guidelines
should be revaluated and modified accordingly. Health care providers should institute
screening for BV regularly, similar to screening for STIs, to potentially diagnose
asymptomatic cases as well as reduce the risk of incident STIs. However, considering the
findings of Ravel and others that indicate that there is a non-Lactobacillus dominant
subgroup of healthy women,(Ravel et al., 2011; Smith & Ravel, 2017; Zhou et al., 2004)
screening practices should implement tools such as molecular testing to discern true cases
of BV.
BV treatment is usually effective. Studies have reported initial cure rates varying
between 80-90% after one month.(Bradshaw et al., 2006; Joesoef & Schmid, 1995)
However, there are high rates of recurrence of BV.(Bradshaw & Brotman, 2015;
Bradshaw & Sobel, 2016; Brotman, 2011; Guedou et al., 2013; Lambert et al., 2013;
Morris et al., 2001) Bradshaw et al. reported the recurrence rate of BV could be as high
as 58% in the first year after treatment.(Bradshaw et al., 2006; Chen et al., 2009) Cook et
al. determined that after the completion of treatment with metronidazole that 30-40% of
women would experience another episode of BV within three months.(Cook et al., 1992)
Comparatively, Wilson et al, reported recurrence rates between 15-30% after
treatment.(Wilson, 2004) Additionally, BV recurrence rates of up to 60% have been
reported within twelve months,(Marshall, 2015) whereas Hillier and Holmes reported
recurrence rates up to 80% within 9 months.(Cook et al., 1992) It may be necessary for
the scientific community to explore alternative methods of treatment for BV since the
current treatment methods are highly ineffective.
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Recurrent and Persistent BV
Recurrent BV, though recognized as a common problem associated with the
treatment of BV,(Hay, 2014) has no universally accepted definition and therefore no
means of definitive diagnosis.(Klatt et al., 2010; Marshall, 2015) However, it is accepted
that the presence of repeated cases of BV after treatment is indicative of recurrent
BV.(Klatt et al., 2010) In literature, recurrent BV is diagnosed in multiple ways. Klatt et
al. defined recurrent BV as “at least three clinic visits within the previous two years that
results in an ICD-9 diagnosis code for BV”.(Klatt et al., 2010) Cook et al. defined
recurrent BV as three or more episodes of BV in the previous year.(Cook et al., 1992)
Chen et al. defined recurrent BV as “filling a vaginal or oral prescription for BV therapy
4-28 weeks post index date”.(Chen et al., 2009) Marshall also defines recurrent BV as
BV cases that “recur one or more times after the completion of an episodic
regimen”.(Marshall, 2015) A standard definition of recurrent BV is required for effective
and efficient diagnosis, treatment and surveillance of this irregular dysbiosis. Nocturnal
application of topical metronidazole twice a week for six months is the only approved
treatment for recurrent BV.(Marshall, 2015) Currently, the treatment of the partners of
women with recurrent BV is not recommended.(Marshall, 2015) The etiology of
recurrent BV is not known, however there are many theories as to why it may occur.
Available research suggests that recurrent BV may be caused by reinfection or
relapse of infection.(Cook et al., 1992; Wilson, 2004) BV reinfection may occur by two
mechanisms, either endogenously or via infection by a partner who has been colonized by
BV associated microorganisms.(Cook et al., 1992) Literature supports the hypothesis that
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recurrent BV occurs by reinfection through studies which indicate that recurrence rates
are lower among women who abstain from sex or use condoms consistently after sex
compared to women who have unprotected sex.(Hutchinson, Kip, & Ness, 2007)
Conversely, Wilson suggests that the lack of evidence to support partner therapy as a
means to reduce recurrent BV indicates that reinfection may not be the cause of recurrent
BV.(Wilson, 2004) Fethers et al. also determined that partner therapy failed to reduce
recurrent BV rates in women.(Fethers et al., 2009) For example, Hay determined, after
reviewing four double blind placebo-controlled clinical trials that after treatment of male
partners there was no difference in the rate of recurrence of BV.(Hay, 2014)
In 2012, Mehta reviewed six randomized clinical trials (RCTs) which assessed the
treatment of male sexual partners for improved bacterial vaginosis outcomes.(Mehta,
2012) It was determined that though the RCTs concluded that male partner treatment did
not provide beneficial effect on BV recurrence in women, that these RCTs were
inherently flawed.(Mehta, 2012) For example, Vejtorp et al. determined that there was no
significant difference in symptom improvement or cure between the intervention and
control groups [RR=1.03, 95% CI:0.83-1.29],(Vejtorp et al., 1988) but their methods
were subpar.(Mehta, 2012) Recruitment and screening methods were not reproducible;
eligibility criteria for both men and women were not reproducible; sample size
calculations were not appropriately addressed; blinding methods were not reported;
adherence was not reported for both men or women; and harms of treatment were not
reported in women or women.(Mehta, 2012) Furthermore it should be noted that many
studies do not assess the treatment of male partners.
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The theory of relapse versus reinfection may be more plausible.(Cook et al.,
1992) Relapse may occur due the inability to reestablish a Lactobacillus dominant
vaginal flora or ineffective treatment.(Cook et al., 1992) Clinical guidelines do not
recommend routine test of cure after treatment of an initial BV infection.(Marshall, 2015)
Relapse of BV infection could indicate persistent BV where positive BV diagnosis
remains unchanged after treatment.(Cook et al., 1992) Thus it is important to consider
prognostic indicators of BV. There is a lack of diagnostic tests which predict BV
recurrence after treatment.(Sobel et al., 2019) Sobel et al. present novel findings where
they illustrate the use of a quantitative PCR-based test in combination with Lactobacillus
Relative Composition and Nugent scores to predict the likelihood of BV
recurrence.(Sobel et al., 2019) They determined that the microbial composition of women
with BV within seven days of completing standard metronidazole treatment determined
the likelihood of BV recurrence.(Sobel et al., 2019) It is important to consider whether
BV is an STI versus a sexually enhanced infection in order to further understand the
etiology of BV and its risk factors and develop enhanced diagnostic and prognostic tests.

Predisposing Factors associated with BV
Numerous risk factors are associated with BV, such as sexual history, intravaginal
practices, contraceptive use, antibiotic use, race, education, age and menstrual
cycle.(Guedou et al., 2013; Ranjit et al., 2018; Schwebke et al., 1999) However data with
respect to risk factors of recurrent BV are lacking.(Guedou et al., 2013) It is uncertain
whether or not BV is an STI.(Guedou et al., 2013; Holzman et al., 2001; Koumans et al.,
2007; Morris et al., 2001) The lack of a known etiologic agent makes it difficult to
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classify BV as an STI.(Bautista, Wurapa, Sateren, et al., 2016; Fethers et al., 2009)
However, current literature suggests that BV is related to sexual activity.(Fethers et al.,
2009; Morris et al., 2001) Factors such as number of lifetime sex partners, women who
have sex with women (WSW), use of a sex toy, early coitarche, frequency of vaginal
intercourse, recent partner change, oral sex, anal sex and history of bacterial STIs, have
been proven in the literature to increase the risk of BV.(Bautista, Wurapa, Sateren, et al.,
2016; Rebecca M. Brotman, 2011; Fethers et al., 2009; Guedou et al., 2013; Hutchinson
et al., 2007; Koumans et al., 2007; Menard, 2011; Morris et al., 2001; Muzny et al., 2013;
Ranjit et al., 2018) Fethers and colleagues reported that BV did not occur in women
without a history of sexual experience.(Fethers et al., 2009) Further to this, they also
determined that there was a strong association between BV and penile-vaginal sex with
multiple sex partners.(Fethers et al., 2009)
Additionally, Morris et al. determined that the diagnosis of BV was positively
associated with a recent sex partner change, increasing number of lifetime sex partners,
WSW and a history of bacterial STIs.(Morris et al., 2001) Furthermore, Madhivanan et
al. presented findings that indicated that Trichomonas vaginalis (TV) was positively
associated with BV.(Madhivanan et al., 2008) Few studies have reported the prevalence
of BV among women who report never having sex.(Fethers et al., 2009) However,
Koumans et al. determined that the prevalence of BV among women who never reported
having had sex was 18.8.%.(Koumans et al., 2007) Papanikolaou et al., assessed a serious
case of recurrent BV in a 17 year old female adolescent.(Papanikolaou, Tsanadis,
Dalkalitsis, & Lolis, 2002) Physical examination revealed an intact hymen and Amsel’s
criteria confirmed the presence of BV.(Papanikolaou et al., 2002) This may indicate that
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other factors are necessary for BV infection,(Bautista, Wurapa, Sateren, et al., 2016;
Koumans et al., 2007) and BV may be a sexually enhanced rather than sexually
transmitted infection.(Bautista, Wurapa, Sateren, et al., 2016)
The association between BV and methods of birth control varies depending on
which methods are used. Studies have shown that combined oral contraceptives,
progestin only contraceptives and condom use,(Brotman, 2011) are protective against
BV.(Bautista, Wurapa, Sateren, et al., 2016; Madden et al., 2012; Menard, 2011; Muzny
et al., 2013; Ranjit et al., 2018) Ranjit et al. reported that the risk of BV increased among
women that used contraceptives on anatomical sites compared to women that did
not.(Ranjit et al., 2018) They postulated that the observed difference among women that
used oral contraceptives compared to those that did not could have been attributed to the
effect of increased levels of estrogen that could potentially support the growth of specific
bacteria responsible for lowering the risk of BV.(Ranjit et al., 2018) Of note, Ranjit et al.
reported that the risk of BV was higher among individuals who used condoms daily
compared to those that used condoms sometimes, however this difference was not
statistically significant. They also determined that oral contraceptives reduced the risk of
BV.(Ranjit et al., 2018) Conversely, consistent condom use has been reported in other
studies to significantly lower the risk of recurrent BV.(Bautista, Wurapa, Sateren, et al.,
2016; Guedou et al., 2013; Hutchinson et al., 2007) The relationship between BV and
intrauterine devices (IUDs) is unclear.(Madden et al., 2012) Some studies have
determined that IUDs increase the risk of BV,(Kenyon et al., 2013) while others
determined that there is a decreased risk.(Madden et al., 2012) Madden and colleagues
did not find a statistically significant association between IUDs and BV.(Madden et al.,
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2012) However, they determined that intravaginal bleeding during the first six months
among IUD users resulted in a twofold increased risk of BV.(Madden et al., 2012) They
further postulated that irregular bleeding may be on the causal pathway between IUD use
and BV.(Madden et al., 2012) Conversely, Joesoef determined that BV was significantly
associated with IUDs.(Joesoef et al., 2001) It is important to consider that there may be
differences in the type of IUDs used in each study (hormone loaded versus copper IUDs).
The aforementioned studies did not differentiate between the types of IUDs used.
Intravaginal practices such as douching, also known as vaginal cleansing or
vaginal washing, have been determined to be associated with BV.(Baisley et al., 2009;
Bautista et al., 2017; Rebecca M. Brotman, 2011; Guedou et al., 2013; Holzman et al.,
2001; Hutchinson, Kip, Ness, & Gynecologic Infection Follow-Through, 2007; Kenyon
et al., 2013; Menard, 2011; Morris et al., 2001; Muzny et al., 2013; Ranjit et al., 2018)
Mixed conclusions about this relationship have been posed in current literature.(Guedou
et al., 2013; Jespers et al., 2014) Some studies have determined that douching increased
the risk of BV infection.(Bautista, Wurapa, Sateren, et al., 2016; Guedou et al., 2013;
Koumans et al., 2007; Morris et al., 2001; Muzny et al., 2013; Ranjit et al., 2018) Ranjit
and colleagues reported a statistically significant difference between women that douched
daily compared to women that douched occasionally and BV.(Ranjit et al., 2018) Women
who douched daily were more likely to have BV.(Ranjit et al., 2018) Additionally,
Schwebke et al., determined that women who refrained from douching were more likely
to be cured of BV.(Schwebke & Desmond, 2007) Conversely, Jespers et al., Demba et al.
and Fethers et al. determined that douching was not associated with BV.(Demba et al.,
2005; Fethers et al., 2009; Jespers et al., 2014) Few studies present findings related to
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douching as a risk factor of recurrent BV. However, Guédou et al. determined that recent
douching was positively associated with recurrent BV,(Guedou et al., 2013) whereas
Klatt et al. determined that douching was not associated with recurrent BV.(Klatt et al.,
2010) Discrepancies observed in the literature may be due to the varying cultural
differences that influence vaginal practices and a lack of understanding of the causal
relationship between BV and douching.(Guedou et al., 2013; Hutchinson et al., 2007)
Hutchinson and colleagues determined that existing abnormal flora influenced the
association between BV and douching.(Hutchinson et al., 2007) They determined that
douching was associated with incident cases of BV among women with intermediate
vaginal flora but not among women with normal vaginal flora.(Hutchinson et al., 2007)
Literature further suggests that women douche following the development of BV to
reduce the effect of the associated symptoms.(Hutchinson et al., 2007) Studies which
assess the relationship between BV and douching using longitudinal versus cross
sectional methods should be further explored.
The risk of BV also varies by race and ethnicity.(Fettweis et al., 2014; Holzman et
al., 2001; Koumans et al., 2007; Menard, 2011; Morris et al., 2001; Muzny et al., 2013;
Ness et al., 2003; Peipert et al., 2008; Ranjit et al., 2018) African American (AA) race is
a risk factor for BV,(Gallo et al., 2012; Kenyon et al., 2013) however, the cause of this
relationship remains unclear.(Holzman et al., 2001; Muzny et al., 2013) AA women are
more likely to have BV compared to non-Hispanic white women.(Bautista et al., 2017;
Ness et al., 2003) Fettweis and colleagues further suggest that AA women are more than
twice as likely to develop BV compared to women of European ancestry (non-Hispanic
Caucasians) and more than twice as likely to have a preterm delivery.(Fettweis et al.,
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2014) AA race is also positively associated with recurrent BV.(Klatt et al., 2010) It is
also important to consider the difference between AA women and women from
continental Africa in terms of the prevalence and recurrence of BV. Torrone et al.
determined that the prevalence of BV was 42.1%, 35.2% and 49.5% among 15-24 year
olds in the Southern African, Sothern/Eastern African and Eastern African regions of
continental Africa respectively.(Torrone et al., 2018) BV occurs in approximately 29% of
US women and approximately 50% of these cases occur among AA women.(Alcendor,
2016) Rates of BV infection are higher among women from continental Africa compared
to AA women.(Alcendor, 2016) Statistically significant differences are also observed
among the vaginal microbiomes of women of different ethnic backgrounds.(Brotman,
2011) Education level is also associated with BV.(Holzman et al., 2001; Ranjit et al.,
2018) Holzman et al. determined that lower education level was a significant predictor of
BV.(Holzman et al., 2001) Ranjit et al. also came to a similar conclusion in their study
where data indicated that BV was most prevalent among illiterate women.(Ranjit et al.,
2018)
Current literature suggests that menstrual cycle is associated with BV.(Bautista,
Wurapa, Sateren, et al., 2016; Hay, 2014; Holzman et al., 2001; Kenyon et al., 2013)
Holzman et al. concluded that BV was more common during the first week of the
menstrual cycle.(Holzman et al., 2001) Bautista and colleagues have also reported a
positive association between BV and the menstrual cycle as well as vaginal
hygiene.(Bautista, Wurapa, Sateren, et al., 2016) For example, the use of cloth or cotton
for menstrual hygiene compared to sanitary pads was found to be a risk factor for
BV.(Baisley et al., 2009; Dahal, Jhendi, Pun, & Maharjan, 2017) A history of pregnancy
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also increases the risk of BV.(Bautista, Wurapa, Sateren, et al., 2016) Broad spectrum
antibiotic use is also a risk factor for BV.(Dahal et al., 2017; Ranjit et al., 2018) Baeten
and colleagues determined that recent antibiotic use was a risk factor for loss of
Lactobacilli which is associated with BV.(Baeten et al., 2009)

The Vaginal Microbiota and BV
The vaginal microbiota is instrumental in female reproductive health.(Rebecca M.
Brotman, 2011) Advancements in bioinformatics allow for the characterization of the
changes in vaginal microbiota during BV through 16S RNA sequencing.(Vitali et al.,
2015) Current literature indicates that there is a correlation between vaginal microbiota
and BV.(Rebecca M. Brotman, 2011; Vitali et al., 2015) A healthy vaginal microbiota
typically presents with a low pH and low levels of species diversity.(Deng et al., 2018)
Community state types (CSTs) can be used to describe the variation in the vaginal
microbiota by classifying them into dominant groups.(Deng et al., 2018; Ravel et al.,
2011) CSTs are dominated by Lactobacillus such as L. crispatus, L. iners, L. gasseri, L.
jensenii or a diverse community.(Deng et al., 2018; Ravel et al., 2011) Vitali and
colleagues determined that L. iners was more common among women infected with BV
compared to L. crispatus which is more common among women with a healthy vaginal
microbiota.(Vitali et al., 2015) They further conclude that Atopobium, Prevotella and M.
hominis were more prevalent among women with BV.(Vitali et al., 2015)
Deng et al. determined that G. vaginalis was the most abundant active species in
BV.(Deng et al., 2018)
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The vaginal metabolome also highlights characteristics of BV; however, few
studies explore this relationship.(Srinivasan et al., 2015) Significant differences have
been demonstrated between the metabolic profiles of women with and without
BV.(Srinivasan et al., 2015) In cases of BV there is a general increase in amines such as
tyramine, trimethylamine and cadaverine.(Srinivasan et al., 2015; Vitali et al., 2015) In
addition to assessing the vaginal metabolome, the frequency and length of time of
sampling needs to be explored. The vaginal microbiome is dynamic and findings from
cross sectional versus longitudinal studies can vary. Literature suggests that there are
high levels of species turnover in the vaginal microbiota.(Gajer et al., 2012) Lambert and
colleagues determined from their longitudinal analysis of the vaginal microbiome of
women with recurrent BV, levels of Lactobacilli decrease long before symptomatic BV
presents.(Lambert et al., 2013) Ravel and colleagues determined through daily
assessment of the vaginal microbiota that prior to symptomatic BV the vaginal
microbiota mainly comprised of strict anaerobes like Atopobium, Prevotella,
Megasphera, BV-associated bacterium 2 and G. vaginalis.

BV and Adverse Sequalae
The epidemiological profile of BV is similar to many common bacterial
STIs.(Bautista, Wurapa, Sateren, et al., 2016) BV also increases the risk of acquiring
many STIs such as human immunodeficiency virus (HIV),(Baisley et al., 2009; Bautista,
Wurapa, Sateren, et al., 2016; Bautista, Wurapa, & Sanchez, 2016; Bautista et al., 2017;
Bradshaw & Brotman, 2015; Gallo et al., 2012; Muzny et al., 2013) Neisseria
gonorrhoeae (NG),(Bautista, Wurapa, Sateren, et al., 2016; Bautista, Wurapa, &
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Sanchez, 2016; Bautista et al., 2017; Bradshaw & Brotman, 2015; Gallo et al., 2012)
CT,(Bautista, Wurapa, Sateren, et al., 2016; Bautista, Wurapa, & Sanchez, 2016; Bautista
et al., 2017; Bradshaw & Brotman, 2015; Gallo et al., 2012) TV and herpes simplex
virus-2 (HSV-2)(Baisley et al., 2009; Bautista, Wurapa, & Sanchez, 2016; Bautista et al.,
2017; Bradshaw & Brotman, 2015; Gallo et al., 2012).(Allsworth & Peipert, 2011;
Kenyon et al., 2013; Koumans et al., 2007) Wiesenfeld et al. determined that the
likelihood of positive NG/CT increased as the abnormality of vaginal flora increased and
that BV was associated with a 4 and 3.4 times increased risk of testing positive for NG
and CT respectively.(Wiesenfeld, Hillier, Krohn, Landers, & Sweet, 2003) Similarly,
Baustista et al determined that there was a 1.5 and 2.4 times increased risk of CT and NG
diagnosis respectively among women diagnosed with BV.(Bautista, Wurapa, & Sanchez,
2016; Bautista et al., 2017) Furthermore, Lactobacillus bacteria produce H2O2 which
inhibits the growth of NG.(Gallo et al., 2012) In cases of BV where Lactobacillus
decrease and the levels of H2O2 also decrease, there is increased risk of NG.(Gallo et al.,
2012) Though research supports that BV increases the risk of STIs through biological
mechanisms, BV can also be a consequence of STIs.(Gallo et al., 2012)
Studies have shown mixed results about the treatment of BV to prevent
acquisition of STIs. Schwebke et al determined that treatment of BV resulted in
significantly lower number of CT cases.(Schwebke & R. Desmond, 2007b) BV has been
associated with concurrent infections of NG/CT, as well as longitudinal studies have
shown that BV is associated with NG/CT bidirectionally.(Bautista, Wurapa, & Sanchez,
2016; Morris et al., 2001; Ness et al., 2005) In addition to BV increasing the risk of
HIV,(Myer et al., 2005) BV also increases HIV viral shedding.(Baisley et al., 2009;
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Koumans et al., 2007) Among women HIV seropositive women, BV increases the risk of
transmission of HIV to male partners.(Bradshaw & Brotman, 2015) There is a twofold
increased risk of HSV-2 among women with BV.(Koumans et al., 2007) Additionally,
BV increases the risk of human papillomavirus (HPV).(Bautista, Wurapa, & Sanchez,
2016; Bautista et al., 2017; R. M. Brotman et al., 2014) Brotman et al. determined that
women with a L. gasseri dominant vaginal microbiota were more likely to clear
detectable HPV from the vaginal microbiota.(R. M. Brotman et al., 2014) Additionally,
they concluded that BV associated vaginal microbiota, low levels of Lactobacillus spp or
L. iners dominant, had the greatest relative proportion of HPV positive samples.(Brotman
et al., 2014) BV is also associated with adverse reproductive outcomes, such as preterm
delivery, intrauterine infection and pelvic inflammatory disease.(Baisley et al., 2009;
Morris et al., 2001; Ness et al., 2003)

Conclusions and Implications for the Future
Conflicts in the literature further highlight what little is known about the etiology
and pathogenesis of BV, recurrent BV and persistent BV. Though we have presented
many known risk factors of BV in this narrative review no true causative agent has been
identified. Further investigation is needed to determine potential predictors that may
differentiate whether or not BV is a sexually transmitted or sexually enhanced disease.
Enhanced analytical techniques such as structural equation modelling or multi-state
Markov models should be implemented to better understand the relationship between
sexual correlates and BV.
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In addition to the current literature which examines the serious associated medical
comorbidities, lack of known etiology and poor long-term treatment, future research
should investigate the predictors and prognostic indicators of recurrent and persistent BV,
differences in the vaginal microbiota of women with recurrent and persistent BV, the
effect of recurrent and persistent BV on incident NG/CT and the effect of treatment of the
aforementioned factors. Emphasis should be places on the novel findings of Sobel et al
with respect to prognostic indicators and further explored. There is a noted lack of
standard definitions of recurrent and persistent BV. This hinders the scientific community
in making definitive conclusions with respect to treatment options of these very common
conditions associated with BV cases. Additionally, the current screening and treatment
guidelines should be reviewed.
Furthermore, the designs of studies to investigate BV need to be addressed. Many
studies measure BV at long intervals or cross sectional. More emphasis should be placed
on the daily assessment of BV. Additionally, studies which examine the vaginal
microbiome of women with BV should place more emphasis on metabolomic
assessments in order to assess the effects of metabolites on the vaginal microbiome.
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MANUSCRIPT 2
Factors Associated with the Recurrence, Persistence and Clearance of Bacterial
Vaginosis among Young African American Women: A Latent Class Analysis
Abstract

Background: While risk factors of recurrent and persistent BV have been explored in the
literature, the long-term incidence patterns of BV remain elusive. Methods: Previously
concluded randomized clinical trial data were analyzed, where oral metronidazole was
the administered treatment. Latent class analysis (LCA) techniques were used to assess
the patterns of multiple episodes of BV over twelve months. Multinomial regression
analysis was used to determine the predictors of class membership. The multivariable
model included age, last BV treatment, douching frequency, birth control, sexual risk
behavior and treatment with metronidazole. Results: A total of 858 African American
women, asymptomatic for BV were included in the analysis. There were three emergent
patterns of multiple cases of BV determined by LCA: persistent (55.9%), recurrent
(3.5%) and clearance (13.5%). Participants who had douched at least once had
significantly lower odds to be in the recurrent class (Adjusted Odds Ratio [adjOR]: 0.55;
95% Confidence Interval [CI]: 0.18-0.63) than participants who never douched. Women
who had sex with women (WSW) had significantly lower odds of belonging to the
persistent class (adjOR: 0.38; 95% CI: 0.22-0.68) and the recurrent class (adjOR: 0.43;
95% CI: 0.23-0.81) than women who did not. Those who were treated with
metronidazole had significantly increased odds of being in the recurrent class (adjOR:
1.92; 95% CI: 1.22-3.03) than those who were not treated. Conclusion: Assessment of
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BV cases revealed distinct patterns of recurrence and persistence of BV despite
treatment, which were significantly associated with age and women having sex with
women.
Keywords
bacterial vaginosis, latent class analysis, clearance, persistence, recurrence

Introduction
Bacterial vaginosis (BV) is a polymicrobial condition with vaginal dysbiosis that
was first documented by Gardner and Dukes in 1955.(Bautista et al., 2016; Gardner &
Dukes, 1955) BV is the most common cause of vaginal discharge,(Bradshaw et al., 2006;
Falconi-McCahill, 2019; Muzny et al., 2019) and is associated with increased risk of
preterm birth, pelvic inflammatory disease and sexually transmitted diseases.(Muzny et
al., 2019) The current recommended forms of treatment include metronidazole or
clindamycin.(Bradshaw et al., 2006; Bunge, Beigi, Meyn, & Hillier, 2009; Faught &
Reyes, 2019) Though short term BV cure rates are high, approximately 80-90%, there are
however high long term recurrence rates of BV post treatment.(Bradshaw et al., 2006)
There is no universally accepted definition of recurrent BV and effective treatment for
recurrent BV does not exist.(Faught & Reyes, 2019) Oral metronidazole is the
recommended form of treatment for symptomatic BV, however, it may not be an
effective treatment for women with recurrent BV who have failed metronidazole
treatment in the past.(Bunge et al., 2009; Faught & Reyes, 2019) The effect of
metronidazole on normalizing vaginal flora in women with asymptomatic BV is not
known. It should be noted that approximately 25% of women with BV experience
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spontaneous resolution of BV.(Bunge et al., 2009) Furthermore, in some cases, BV
continues to persist. Thus, BV incurs alarmingly high treatment costs, estimated to be
$4.8 billion annually, and the high prevalence of BV is of public health concern.(FalconiMcCahill, 2019)
The National Health and Nutrition Examination Survey (NHANES) data between
2001 and 2004 estimated the prevalence of BV in the United States (US) to be
29.2%.(Falconi-McCahill, 2019) The prevalence of BV varies by race and ethnicity with
Black and Hispanic women having a higher prevalence of BV compared to White and
Asian women.(Falconi-McCahill, 2019) Cultural backgrounds also influence the use of
intravaginal practices such as vaginal douching which is associated with BV.(Aslan &
Bechelaghem, 2018) Vaginal douching involves the use of cleansing solution in the
vagina,(Yanikkerem & Yasayan, 2016) and the effects of this practice have been disputed
as some literature has found varying effects of douching.(Gresenguet, Kreiss, Chapko,
Hillier, & Weiss, 1997; Hutchinson, Kip, Ness, & Gynecologic Infection FollowThrough, 2007; Tevi-Benissan et al., 1997) Additionally, sexual activity increases the
risk of incident and recurrent BV.(Falconi-McCahill, 2019; Ranjit, Raghubanshi,
Maskey, & Parajuli, 2018) Women who have sex with women (WSW) and women who
have sex with multiple male sex partners are at increased risk of BV.(Falconi-McCahill,
2019) Furthermore, women who remain with their male sex partner after treatment are at
increased risk of recurrent BV.(Falconi-McCahill, 2019) Literature states that hormonal
contraception and condom use are protective against BV.(Bautista et al., 2016; FalconiMcCahill, 2019; Ranjit et al., 2018) Though there are multiple known risk factors of BV,
the etiology of BV continues to remain unknown.(Bautista et al., 2016) Novel approaches
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are needed to further elucidate the etiology of BV. One such possible method is Latent
Class Analysis (LCA).
LCA has been used in research to assign participants to discrete, mutually
exclusive groups known as latent classes through a probabilistic approach.(Kongsted &
Nielsen, 2017; Schreiber, 2017) Latent classes are determined based on selected observed
categorical variables.(Lanza, Collins, Lemmon, & Schafer, 2007) LCA has been
increasingly popular in behavioral science research to investigate latent risk
factors.(Okeke, Clement, McKellar, & Stout, 2018) Okeke and colleagues have
implemented LCA techniques to investigate health care utilization behaviors and
disengagement from HIV care.(Okeke et al., 2018) LCA has also been used in BV
research by Jespers et al.(Jespers et al., 2012) They identified two types of “normal flora”
and one “BV type flora” with LCA, which were significantly associated with various
Lactobacillus bacteria.(Jespers et al., 2012) Though their research used LCA to examine
BV and its relationship with vaginal flora, to the best of our knowledge, LCA has not
been used to examine demographic and behavioral characteristics of BV and BV
incidence patterns after treatment. Our study aimed to identify BV incidence patterns
over a twelve-month period and evaluate the demographic and behavioral risk factors
associated with these patterns among women with BV at baseline. This is of public health
importance due to the high rates of recurrence of BV.

Materials and Methods
Study Design
We conducted a retrospective analysis of data from African American women of
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reproductive age who participated in a randomized clinical trial (RCT) which
investigated home screening for BV to prevent sexually transmitted diseases (STDs). The
RCT was conducted in six geographic locations (Baltimore, Maryland; Birmingham,
Alabama; Durham and Raleigh, North Carolina; Pittsburgh, Pennsylvania; and San
Francisco, California). The methodology used for the RCT has been previously
described.(Schwebke et al., 2016) Here, we briefly summarize the key aspects of the
study.
Women at increased risk for STDs who had asymptomatic BV were recruited
from STD, family planning, obstetrics-gynecology and clinical research
clinics.(Schwebke et al., 2016) Participants were eligible for the study if they had vaginal
pH >4.5 and >20% clue cells on vaginal wet preparation microscopy and did not
complain of abnormal vaginal discharge or odor. Women who exhibited BV symptoms,
such as increased vaginal discharge and vaginal odor, were not included in the study.
Eligible participants were randomized to treatment and control groups, and followed-up
for a period of twelve months. Women randomized to the treatment group received
500mg of oral metronidazole for seven days upon enrollment. Participants received home
testing kits every two months to collect vaginal samples for BV testing. Every four
months an additional swab was collected to test for chlamydia and gonorrhea. Women in
the treatment arm received 500mg of oral metronidazole for seven days after every
positive BV result. Women in the control arm did not receive treatment for asymptomatic
BV at any time during the study, in accordance with Centers for Disease Control and
Prevention (CDC) guidelines.(Workowski & Berman, 2010) All women, irrespective of
the arm they were randomized to, could receive treatment if they developed symptoms
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during the follow-up period from their respective primary care physicians. Institutional
Review Board (IRB) approvals were obtained by all participating sites prior to the
conduct of the initial study. The current study was approved by the Florida International
University IRB.

Measures
Participants were trained to obtain self-collected swabs. Swabs were rolled across
a microscope slide and sent to a lab for evaluation. Nugent Scores (NS) of vaginal smears
were used to assess the presence of BV every two months. The slides were gram-stained
and assessed for BV using NS. NS between 0-3 are considered to not have BV, 4-6
intermediate flora and 7-10 BV. For this study, a NS between 0-6 was considered as ‘no
BV’ and 7-10 indicated ‘BV’.(Mohammadzadeh, Dolatian, Jorjani, & Alavi Majd, 2014)
Baseline demographic, medical and sexual risk behavior characteristics were assessed
using a self-administered questionnaire. Age, race, ethnicity and highest level of
education were measured. Medical history assessed included prior antibiotic use (past 30
days), prior lifetime episodes of BV (never, once, 2-4 times, ≥ 5 times), prior lifetime
treatment for BV (≤6 months, 7-12 months, ≥12 months ago), prior pregnancy (yes/no)
and frequency of vaginal douching (ever/never). Types of birth control used in the past
year were also assessed; birth control pills, birth control patch, Nuva-ring, condoms,
spermicide cream, Depo-Provera shot, intra-uterine device (IUD) and other. Sexual risk
behavior characteristics evaluated in the past year included; number of different sex
partners, number of oral sex partners (receptive), number of unprotected anal sex
partners, number of unprotected vaginal sex partners, women who have sex with women
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and new sex partners. Randomization arms were also assessed; treatment with
metronidazole and no treatment.

Statistical Analysis
There were 1,365 women enrolled in the original RCT and 1,160 agreed to the
future use of the data for research. For this study, we only included women who selfidentified as African American (n=977). African American women were selected due to
their increased risk of BV and unique cultural attributes. For LCA of BV patterns over a
twelve-month period, we used the BV results (yes/no) at months two, four, six, eight, ten
and twelve. Baseline BV results were excluded since all women had BV at baseline and
inclusion of these participants may bias the results. Participants with missing BV results
for all timepoints were excluded from the analysis (119 women; 12.2%). Listwise
deletion was selected since there was a large enough sample and BV results were missing
completely at random. Consequently, 858 African American women were included in the
analysis. There were no statistically significant differences with respect to age, education,
ethnicity and race between women that were included compared to those who were
excluded. Baseline participant characteristics were described using frequencies for
categorical variables and means and standard deviations for continuous variables. Age
was the only continuous variable and was categorized for easy comparison of groups.
Chi-squared or Fisher exact tests for categorical variables were used as appropriate to
assess differences by latent class.
Latent classes were modeled using PROC LCA in SAS.(Lanza et al., 2007) We
assessed the model fit statistics of models which included two to five latent classes. The
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maximum number of iterations for each model was 9000 and the seed was 1000.
Bayesian information criterion (BIC), adjusted Bayesian information criterion (aBIC),
Akaike information criterion (AIC) and entropy were used to identify the best
model.(Lanza et al., 2007) Participants were assigned to latent classes based on the
highest posterior probability of membership. We used multinomial logistic regression to
examine the relationship between baseline demographic characteristics, medical history,
sexual risk behavior in the past year and latent class membership. Baseline predictors
evaluated behavior and characteristics among participants of the previous year. Variables
with Chi-squared test p-values <0.2 were included in the multivariable multinomial
logistic regression, as seen in literature.(Zellner, Keller, & Zellner, 2004) Age, frequency
of douching, last BV treatment, prior pregnancy, birth control (Depo Provera shot),
unprotected anal sex partners, sex with other women, new sex partners and treatment
with metronidazole were included in the final model. SAS version 9.4 (SAS Institute Inc,
Cary, NC) was used to clean and analyze all data and LCA was conducted using the
SAS-based add on package PROC LCA, version 1.3.2 (University Park, PA).

Results
Participant Characteristics
The mean age of the sample was 21.25 (SD: ±2.12) years. Chi-squared test results
showed significant associations between some baseline variables and latent classes. All
women were African American and 3.85% of women also self-identified as
Hispanic/Latino (p=0.45). Most women were educated, with 48.4% completing more
than a high school diploma or GED (p=0.48). Participant responses indicated a lack of
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prior antibiotic use in the past 30 days (0.1%; p=0.96), most women had never been
diagnosed with BV (54.2%; p=0.25) and of those who reported prior episodes of BV,
most (61.9%; p=0.04) were treated ≤6 months ago. Additionally, 57.0% of women
reported a prior pregnancy (p=0.05) and 50.4% reported having douched at least once
(p=0.02). Various forms of birth control were used by majority of women (93%) such as,
birth control pills/patches (19.6%; p=0.98), Nuva Ring (4.2%; p=0.33), condoms (77.6%;
p=0.69), Depo-Provera shot (15.7%; p=0.04), IUDs (9.8%; p=0.34) and spermicide
(1.2%, p=0.42). All women engaged in sexual activity in the prior year. Most women had
two or more sex partners (76.6%; p=0.75) as well as two or more oral sex partners
(52.4%; p=0.39) in the prior year. There were 150 (17.5%; p=0.16) women that had
engaged in unprotected anal sex, and 799 (93.1%; p=0.95) women that had engaged in
unprotected vaginal sex. Moreover, 97 (11.3%; p=0.01) women reported having had sex
with other women and 418 (48.7%; p<0.01) had new sex partners. Approximately half of
the sample were assigned to the treatment arm (N=438; 51%; p<0.01). The
aforementioned p-values were associated with the comparison between latent classes.
Table one details the participant characteristics of the study sample stratified by latent
class.

Latent Class Description
A three-class model was selected based on its optimal fit for the data. BIC, aBIC,
AIC and entropy scores were used to compare a five-class (AIC-99.79, BIC-261.45,
aBIC-153.47, Entropy-0.63), four-class (AIC-97.05, BIC-225.43, aBIC- 139.68, Entropy0.58), three-class (AIC-102.90, BIC-197.99, aBIC-134.47, Entropy-0.61), and two-class
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model (AIC-120.17, BIC-181.98, aBIC-140.69, Entropy-0.65). Classes were named
based on item-response probabilities as follows: “persistent” (55.9%), “recurrent”
(30.5%) and “clearance” (13.5%) (Table 2). The persistent class was characterized by
high probability (>77%) of being positive for BV (NS:7-10) at each time point (months
two, four, six, eight, ten and twelve). This class had the highest probability of BV at
every timepoint, with the highest probability (87%) at month ten. Women in the recurrent
class alternated between decreasing (as low as 13%) and increasing (as high as 31%)
probabilities of having BV at each timepoint. The probability of BV in this class
decreased between months two and six and then steadily increased until month twelve.
Finally, women in the clearance class had a consistently decreasing probability of BV
from 72% to 8% from months two to ten and increased to 19% at month twelve. This
class had the lowest probability (8%; month ten) of BV of all three classes.

Factors associated with Latent Class Membership
Women >21 old years were significantly more likely to be in the persistent class
(adjOR: 1.90; 95% CI: 1.23-2.95), or recurrent class (adjOR: 1.88; 95% CI: 1.17-3.00)
than the clearance class. Women who had experienced a prior episode of BV and
received treatment seven to twelve months ago had significantly lower odds of being in
the persistent class compared to clearance class (adjOR: 0.34; 95% CI: 0.18-0.63) than
women who did not have a prior episode of BV. Participants who douched at least once
had significantly lower odds of being in the recurrent class compared to clearance class
(adjOR: 0.55; 95% CI: 0.35-0.87) than participants who never douched. WSW also had
significantly lower odds of being in the persistent class (adjOR: 0.38; 95% CI: 0.22-0.68)

44

or the recurrent class (adjOR: 0.43; 95% CI: 0.23-0.81) compared to clearance class than
women who did not. Those who were randomized to the treatment arm were significantly
more likely to be in the recurrent class versus the clearance class (adjOR: 1.92; 95% CI:
1.22-3.03) than those who did not.

Discussion
Our findings illustrate distinct patterns of multiple cases of BV over a twelvemonth period. Through LCA, we were able to elucidate three distinct patterns;
persistence, recurrence and clearance. Of these three groups, two groups (persistence and
recurrence) were at significantly increased risk of multiple episodes of BV. Our evidence
supports the hypothesis that older age, unprotected anal sex and treatment with
metronidazole were associated with risk of recurrence and/or persistence of BV. We also
determined that women who reported a history of douching, and women who have sex
with women, had lower odds of being in either BV persistence or recurrence groups.
Rates of BV recurrence have been evaluated in the literature; however, this is the first
study to characterize BV patterns over a twelve-month period using LCA. The proportion
of women assigned to the treatment arm classified as persistent was high, and highlights
the poor efficacy of oral metronidazole to reduce the long-term occurrence of multiple
cases of BV.
Although women who were assigned to the treatment arm were less likely to be
classed as persistent, this observation was not statistically significant (adjOR: 0.79; 95%
CI: 0.52-1.20). Conversely, women who were assigned to the treatment arm were
significantly more likely to be classed in the recurrent compared to clearance class
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(adjOR: 1.92; 95 % CI:1.22-3.02). Standard BV treatment includes a course of 500mg of
oral metronidazole for seven days for symptomatic cases.(Faught & Reyes, 2019)
Standard BV treatment was administered to all participants who tested positive for BV in
the treatment arm; the follow-up questionnaire did not fully assess symptoms after
baseline. It should be noted that clinical guidelines do not recommend the treatment of
asymptomatic BV.(Guise et al., 2001) Furthermore, literature also does not support
standard BV treatment for recurrent BV.(Faught & Reyes, 2019) If it is assumed that the
mechanism of asymptomatic and symptomatic BV are the same, the increased likelihood
of multiple episodes of BV may have been caused by ineffective treatment of those
randomized to the treatment arm.(Faught & Reyes, 2019) Faught et al. present alternative
treatment methods for recurrent BV such as metronidazole 750 mg/miconazole 200 mg
for five nights each month for twelve months or metronidazole vaginal gel (0.75%) for
three to six months.(Faught & Reyes, 2019) Furthermore, the mechanism for recurrent
BV is unknown. It is hypothesized that recurrent BV may be caused by residual infection
due to the persistence of Gardnerella vaginalis, which is resistant to metronidazole
treatment.(Faught & Reyes, 2019) Women who received BV treatment 7-12 months ago
were less likely to be classed as persistent (adjOR: 0.34; 95% CI: 0.18-0.63). This finding
is unclear and may be an artefact due to the skewed distribution observed among the
categories.
Though BV is not considered an STI, as there is no known pathogen, it is
associated with sexual activity.(Falconi-McCahill, 2019; Faught & Reyes, 2019)
Specifically, irregular condom use, multiple sex partners and having a consistent sex
partner are associated with recurrent BV.(Falconi-McCahill, 2019; Faught & Reyes,
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2019) We determined that the only significant associations between sexual activity and
class membership occurred among WSW. WSW were less likely to be classed as
persistent (adjOR: 0.38; 95% CI: 0.22-0.68) or recurrent class (adjOR: 0.43; 95% CI:
0.23-0.81). Our findings are similar to those of Muzny et al. who determined that WSW
were less likely to be diagnosed with BV (adjOR: 0.08; 95% CI: 0.01-0.74).(Muzny,
Sunesara, Austin, Mena, & Schwebke, 2013) Contrary to these findings, FalconiMcCahill et al. present data which concludes that there is an increased risk of BV among
WSW.(Falconi-McCahill, 2019) The discrepancies observed may be due to varying
practices among WSW such as vaginal lubricant use, oral-anal sex and improper cleaning
of vaginal sex toys.(Muzny et al., 2013) Women engaging in unprotected anal sex with
one partner versus none were more likely to be classed as persistent (adjOR: 2.45; 95%
CI: 1.21-4.98). This is consistent with literature which suggests that unprotected anal sex
increases the risk of BV.(Cherpes, Hillier, Meyn, Busch, & Krohn, 2008) Though women
who had one unprotected anal sex partner were more than twice as likely to be in the
persistent class compared to the clearance class, women with two or more sex partners
did not have a significant association with class membership. Of note, though the
confidence interval did not include one, the association between anal sex and latent class
did not yield a significant p-value (type III). The lack of a significant relationship may be
a result of the small number of women who had unprotected anal sex with two or more
partners. The distribution did not allow for significant results and the confidence interval
observed may have resulted from chance. This may be a spurious finding.
Intravaginal practices such as douching are also associated with the risk of
BV.(Aslan & Bechelaghem, 2018; Brotman et al., 2008) However, the effects of
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douching vary.(Aslan & Bechelaghem, 2018; Gresenguet et al., 1997; Hutchinson et al.,
2007; Pavlova & Tao, 2000; Tevi-Benissan et al., 1997) Our results show that women
who douched at least once were less likely to be classed as recurrent versus clearance
(adjOR: 0.55; 95% CI: 0.35-0.87) as compared to women who had never douched. This
association may be the result of the postulated beneficial effects of vaginal douching such
as removal of semen after sex, and alleviation of vaginal irritation.(Aslan &
Bechelaghem, 2018; Tevi-Benissan et al., 1997) The removal of semen decreases the
load of sexually transmitted pathogens.(Tevi-Benissan et al., 1997) Furthermore, the
temporal association between BV and vaginal douching is also disputed.(Hutchinson et
al., 2007) It is possible that women douche to alleviate the symptoms of BV as well as
that vaginal douching causes BV.(Hutchinson et al., 2007) Hutchinson et al. determined
through prospective longitudinal analyses that douching was not associated with
BV,(Hutchinson et al., 2007) however, cross-sectional studies have determined that
douching was associated with BV.(Hutchinson et al., 2007; Ranjit et al., 2018) Our
analysis was cross-sectional, thus the bidirectional nature of the association between BV
and vaginal douching could not be assessed. There were no statistical differences in terms
of douching between the persistent and clearance class. This may suggest that douching
may only be beneficial for women with recurrent BV. There may be inherent differences
in the vaginal microbiota of women classed as recurrent versus persistent which could
account for this observation. Older women (>21 years) were more likely to be members
of the persistent and recurrent classes compared to the clearance class, indicating that
older women were more likely to experience multiple episodes of BV over a twelvemonth period. BV is the most common vaginal dysbiosis among women of reproductive
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age.(Ranjit et al., 2018) Our findings are consistent with those of Ranjit et al. who
determined that BV was least prevalent among women <21 years.(Ranjit et al., 2018)
Though our study is novel in its approach, it is also subject to some limitations.
There was no test of cure for BV done by the RCT from which data for this study was
acquired. Therefore, it is possible that participants did not take the medication as
prescribed. Furthermore, the treatment administered has been shown in literature to be
ineffective. Additionally, all responses received on the baseline questionnaire were selfreported and subject to recall and social desirability bias. Consequently, sexual risk
behavior may have been underreported. The analysis was further limited by the lack of
inclusion of time varying predictors though the outcome is based on a twelve-month
assessment. The presence or absence of BV symptoms were not assessed after baseline
and therefore could not be accounted for in the analysis. There is also limited
generalizability of results since only African American women were included in the
analysis. For future research, Latent Transition Analysis could be explored to assess the
risk factors associated with transitions between BV states at each time point and include
time varying predictors. Our study also failed to incorporate the use of microbiota data.
For future research, the use of metabolomics to examine the longitudinal changes in the
vaginal microbiome should be conducted to assess the microbiological factors which
contribute to the recurrence and persistence of BV. Additionally, the host immune
response should be considered. Furthermore, LCA can be used to create classes which
combine epidemiologic and microbiome data to comprehensively assess the multiple
predictors of repeated cases of BV. Considering the lack of knowledge of the
mechanisms of recurrent and persistent BV, novel analytical approaches are needed to
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examine these phenomena. Examination of epidemiologic and microbiome data in silo is
not sufficient.
Here we present novel findings that classify women based on BV persistence,
recurrence and clearance over a twelve-month period. Our findings illustrate high
incident cases of BV. Women aged 21 years and over, who douched at least once, who
engaged in sexual activity with other women in the past year, and received metronidazole
treatment were significantly more likely to be in the recurrent class compared to the
clearance class. Similarly, women aged 21 years and over who had sex with other women
were significantly more likely to have a persistent case of BV. Efforts should be made to
evaluate alternative treatment for recurrent and persistent cases of asymptomatic BV.
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Tables
Table 1: Participant Characteristics stratified by Latent Class
Characteristics

Categories
Levels
Overall

Latent Classes (N=858)
Persistent
Recurrent
Clearance
(N=480;
(N=262,
(N=116;
55.9%)
30.5%)
13.5%)

Demographic Variables
Age, n (%)

p valuea

0.03
≤21 years
>21 years

355 (41.4%)
503 (58.6%)

184 (38.3%)
296 (61.7%)

111 (42.4%)
151 (57.6%)

60 (51.7%)
56 (48.3%)

No HS
HS
More than HS

151 (17.6%)
292 (34.0%)
415 (48.4%)

85 (17.7%)
173 (36.0%)
222 (46.3%)

46 (17.6%)
78 (29.8%)
138 (52.7%)

20 (17.2%)
41 (35.3%)
55 (47.4%)

Hispanic/Latino
Not Hispanic/Latino

33 (3.8%)
825 (96.2%)

15 (3.1%)
465 (96.9%)

12 (4.6%)
250 (95.4%)

6 (5.2%)
110 (94.8%)

Education, n (%)

0.48

Ethnicity, n (%)

0.45

Medical History
Prior Antibiotic Useb, n (%)

0.96
Yes
Noc

45 (5.2%)
813 (94.8%)

26 (5.4%)
454 (94.6%)

13 (5.0%)
249 (95.0%)

6 (5.2%)
110 (94.8%)

Once
2-4 times
5 or more times
Neverd

176 (20.5%)
161 (18.8%)
56 (6.5%)
465 (54.2%)

93 (19.4%)
83 (17.3%)
26 (5.4%)
278 (57.9%)

57 (21.8%)
51 (19.5%)
22 (8.4%)
132 (50.4%)

26 (22.4%)
27 (23.3%)
8 (6.9%)
55 (47.4%)

Prior Episodes of BV, n (%)

0.25

Last BV treatment, n (%)

0.04
54

≤6 months ago
7-12 months ago
≥12 months ago
Nevere

154 (18.0%)
92 (10.7%)
148 (17.3%)
464 (54.1%)

83 (17.3%)
38 (7.9%)
81 (16.9%)
278 (57.9%)

50 (19.1%)
34 (13.0%)
46 (17.6%)
132 (50.4%)

21 (18.1%)
20 (17.2%)
21 (18.1%)
54 (46.6%)

Prior Pregnancy, n (%)

0.05
Yes
No

493 (57.5%)
365 (42.5%)

292 (60.8%)
188 (39.2%)

135 (51.5%)
127 (48.4%)

66 (56.9%)
50 (43.1%)

Douching History, n (%)

0.02
At least once
Never

432 (50.3%)
426 (49.7%)

254 (52.9%)
226 (47.1%)

113 (43.1%)
149 (56.9%)

65 (56.0%)
51 (44.0%)

Birth Control Methods
Pills/Patch, n (%)

0.98
Yes
No

168 (19.6%)
690 (80.4%)

95 (19.8%)
385 (80.2%)

51 (19.5%)
211 (80.5%)

22 (19.0%)
94 (81.0%)

Yes
No

36 (4.2%)
822 (95.8%)

17 (3.5%)
463 (96.5%)

15 (5.7%)
247 (94.3%)

4 (3.5%)
112 (96.5%)

Yes
No

666 (77.6%)
192 (22.4%)

377 (78.5%)
103 (21.5%)

202 (77.1%)
60 (22.9%)

87 (75.0%)
29 (25.0%)

Nuva Ring, n (%)

0.33

Condoms, n (%)

0.69

Depo-Provera Shot, n (%)

0.04
Yes
No

126 (14.7%)
732 (85.3%)

58 (12.1%)
422 (87.9%)

49 (18.7%)
213 (81.3%)

19 (16.4%)
97 (83.6%)

Intra-Uterine Device, n (%)

0.34
Yes
No

84 (9.8%)
774 (90.2%)

50 (10.4%)
430 (89.6%)

27 (10.3%)
235 (89.7%)

7 (6.0%)
109 (94.0%)

Spermicide, n (%)

0.42
Yes
No

10 (1.2%)
848 (98.8%)

7 (1.5%)
473 (98.5%)
55

3 (1.2%)
259 (98.8%)

0 (0.0%)
116

(100.0%)
No Birth Control, n (%)

0.42
Yes
No

60 (7.0%)
798 (93.0%)

36 (7.5%)
444 (92.5%)

14 (5.3%)
248 (94.7%)

10 (8.6%)
106 (91.4%)

One
Two or more

201 (23.4%)
657 (76.6%)

115 (24.0%)
365 (76.0%)

62 (23.7%)
200 (76.3%)

24 (20.7%)
92 (79.3%)

None
One
Two or more
Unprotected Anal Sex Partners, n (%)
None
One
Two or More
Unprotected Vaginal Sex Partners, n (%)
None
One
Two or more
Sexual Activity with Other Women, n (%)
Yes
No
New Sex Partners, n (%)
Yes
No
Treatment Arm, n (%)
Yes
No
HS- High school
BV- Bacterial vaginosis

101 (11.8%)
307 (35.8%)
450 (52.4%)

56 (11.7%)
177 (36.9%)
247 (51.5%)

30 (11.5%)
83 (31.7%)
149 (56.9%)

15 (12.9%)
47 (40.5%)
54 (46.6%)

708 (82.5%)
129 (15.0%)
21 (2.4%)

384 (80.0%)
83 (17.3%)
13 (2.7%)

221 (84.4%)
36 (13.7%)
5 (1.9%)

103 (88.8%)
10 (8.6%)
3 (2.6%)

59 (6.9%)
424 (49.4%)
375 (43.7%)

32 (6.7%)
239 (49.8%)
209 (43.5%)

17 (6.5%)
128 (48.9%)
117 (44.7%)

10 (8.6%)
57 (49.1%)
49 (42.2%)

Sexual Risk Behaviorf
Different Sex Partners, n (%)

0.75

Oral Sex Partnersg, n (%)

0.39

0.16

0.95

0.01
97 (11.3%)
761 (88.7%)

48 (10.0%)
432 (90.0%)

26 (9.9%)
236 (90.1%)

23 (19.8%)
93 (80.2%)

418 (48.7%)
440 (51.3%)

224 (46.7%)
256 (53.3%)

129 (49.2%)
133 (50.8%)

65 (56.0%)
51 (44.0%)

438 (51.0%)
420 (49.0%)

211 (44.0%)
269 (56.0%)

170 (64.9%)
92 (35.1%)

57 (49.1%)
59 (50.9%)

0.19

<0.01
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a

p values compare latent classes
Antibiotic use in the past 30 days
c
No prior and unsure of antibiotic use in the past 30 days
d
Never diagnosed and unsure if diagnosed
e
Never treated and unsure of treatment
f
In the past year
g
Receptive oral sex
b

57

Table 2: Crude and Adjusted Odds Ratios for Risk Factors Associated with Latent Class by Multinomial Logistic Regression
Analysis
Characteristics

Persistent vs Clearance
Crude OR
(95% CI)

Demographic Variables
Age
>21 years 1.72 (1.15-2.59)
≤21 years
-

Recurrent vs Clearance

Adjusted ORa
(95% CI)

Crude OR
(95% CI)

1.90 (1.23-2.95)
-

1.46 (0.94-2.26)
-

Adjusted ORa
(95% CI)

1.88 (1.17-3.00)
-

Education
HS 0.99 (0.55-1.80)
More than HS 0.95 (0.54-1.68)
No HS
Ethnicity
Hispanic/Latino 0.59 (0.22-1.56)
Not
Hispanic/Latino
Medical History
Prior Antibiotic Useb
Yes 1.05 (0.42-2.61)
Noc
Prior Episodes of BV
Once 0.71 (0.42-1.19)
2-4 times 0.61 (0.36-1.03)
≥5 times 0.64 (0.28-1.49)
Neverd
Last BV treatment

-

0.83 (0.43-1.58)
1.09 (0.59-2.01)
-

-

-

0.88 (0.32-2.4)
-

-

-

0.96 (0.36-2.58)
-

-

-

0.91 (0.52-1.60)
0.79 (0.45-1.38)
1.15 (0.48-2.73)
-

-
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≤6 months ago 0.77 (0.44-1.35)

0.74 (0.42-1.32)

0.97 (0.54-1.78)

0.98 (0.53-1.82)

7-12 months ago 0.37 (0.20-0.68)
>12 months ago 0.75 (0.43-1.31)
Nevere
Prior Pregnancy
Yes 1.18 (0.78-1.77)
No
Douching History
At least once 0.88 (0.59-1.33)
Never
Birth Control Methods
Pills/Patch
Yes 1.05 (0.63-1.77)
No
Nuva Ring
Yes 1.03 (0.34-3.12)
No
Condoms
Yes 1.22 (0.76-1.96)
No
-

0.34 (0.18-0.63)
0.68 (0.38-1.21)
-

0.70 (0.37-1.31)
0.90 (0.49-1.64)
-

0.68 (0.35-1.30)
0.90 (0.48-1.68)
-

1.08 (0.69-1.67)
0.80 (0.53-1.22)
-

0.81 (0.52-1.25)
0.60 (0.38-0.93)
-

0.70 (0.44-1.13)
0.55 (0.35-0.87)
-

-

1.03 (0.59-1.80)
-

-

-

1.70 (0.55-5.24)
-

-

-

1.12 (0.67-1.87)
-

-

Depo-Provera Shot
Yes 0.70 (0.40-1.23)
No
Intra-Uterine Device

0.67 (0.37-1.20)
-

1.17 (0.66-2.10)
-

1.26 (0.69-2.30)
-

Yes 1.81 (0.8-4.1)
No
-

-

1.79 (0.76-4.24)
-

-

Yes 0.86 (0.41-1.79)
No
-

-

0.60 (0.26-1.39)
-

-

None
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Sexual Risk Behaviorf
Different Sex Partners
Two or More 0.83 (0.50-1.36)
0.84 (0.49-1.43)
One
Oral Sex Partnersg
One 1.01 (0.52-1.94)
0.88 (0.43-1.81)
Two or more 1.23 (0.65-2.33)
1.38 (0.69-2.76)
None
Unprotected Anal Sex Partners
One 2.23 (1.12-4.44)h
2.45 (1.21-4.96)h
1.68 (0.80-3.51)
1.80 (0.85-3.82)
Two or More 1.16 (0.33-4.16)
1.54 (0.41-5.69)
0.78 (0.18-3.31)
1.06 (0.24-4.71)
None
Unprotected Vaginal Sex Partners
One 1.31 (0.61-2.82)
1.32 (0.57-3.06)
Two or More 1.33 (0.61-2.89)
1.41 (0.60-3.29)
None
Sexual Activity with Other Women
Yes 0.45 (0.26-0.78)
0.38 (0.22-0.68)
0.45 (0.24-0.82)
0.43 (0.23-0.81)
No
New Sex Partners
Yes 0.69 (0.46-1.03)
0.71 (0.47-1.09)
0.76 (0.49-1.18)
0.76 (0.48-1.20)
No
Treatment Arm
Yes 0.81 (0.54-1.22)
0.79 (0.52-1.20)
1.91(1.23-2.98)
1.92 (1.22-3.02)
No
HS- High school
a
The model was adjusted for age, last BV treatment, douching frequency, use of Depo-Provera shot, use of IUDs, women who
have sex with women in the past year, unprotected anal sex in the past year, new sex partners in the past year and treatment.
b
Antibiotic use in the past 30 days
c
No prior and unsure of antibiotic use in the past 30 days
d
Never diagnosed and unsure if diagnosed
e
Never treated and unsure of treatment
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f

In the past year
Receptive oral sex
h
p value >0.05
g
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MANUSCRIPT 3
Risk of Chlamydia and Gonorrhea among young African American women with
Persistent and Episodic Bacterial Vaginosis
Abstract
Background: The purpose of this study was to assess the influence of episodic and
persistent bacterial vaginosis (BV) on incident Chlamydia trachomatis (CT) and
Neisseria gonorrhoeae (NG) infection among young African American women in the
US. Methods: Data from 428 African American women who were previously enrolled in
a randomized clinical trial to assess the efficacy of metronidazole treatment of
asymptomatic BV to reduce incident CT and NG infection were included in this
secondary data analysis. Persistent cases of BV were defined as being positive for BV at
month two, four and six. Women who were negative for BV at month two, four and six
were classified as no BV. All other cases were defined as episodic BV. Incident STI was
defined as any new case of CT or NG at month eight. Factors associated with STI
acquisition were determined using Binary Logistic Regression. Results: Most women
were ≤21 years (55.8%) and completed some post high school/GED education (50.9%).
There were 179 (41.8%; 95 % Confidence Interval [CI]: 37.1%-46.7%) women with
persistent BV and 204 (47.7%; 95% CI: 42.8%-52.5%) women with episodic BV. About
8.6% (95% CI: 6.2%-11.7%) of women tested positive for CT and/or NG. Fisher’s exact
test demonstrated a significant association between BV status and STI acquisition.
Women with high school or more than high school education (adjusted Odds Ratio
(adjOR): 0.38; 95%CI: 0.15-0.92; and adjOR: 0.31; 95%CI: 0.13-0.73) had decreased
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odds of developing an STI. Education was the only significant predictor in the final
model. Women with no BV did not acquire an STI. Conclusion: Incident STIs were only
observed among women with BV. Higher education was associated with lower odds of
STI acquisition.

Keywords
bacterial vaginosis, chlamydia, gonorrhea

Introduction
Reproductive tract infections (RTIs) among women are of significant public
health concern.(Diadhiou et al., 2019) Studies have shown that RTIs are one of the most
significant causes of reproductive morbidity.(Diadhiou et al., 2019) Vaginal dysbiosis
and sexually transmitted infections (STIs) are the two major causes of RTIs.(Diadhiou et
al., 2019) These include infections such as bacterial vaginosis (BV), Chlamydia
trachomatis (CT), and Neisseria gonorrhoeae (NG).(Diadhiou et al., 2019) BV is a
polymicrobial vaginal dysbiosis characterized by a decrease in Lactobacillus bacteria and
an increase in anaerobic organisms.(Ness et al., 2005) BV-associated microorganisms
produce substances such as mucin-degrading enzymes, cytokines, and inflammatory
mediators, which increase the susceptibility to STIs, specifically, CT and NG.(Allsworth,
Lewis, & Peipert, 2008; Allsworth & Peipert, 2011) Numerous studies have found BV to
be associated with CT and NG, however, the majority of these studies were cross
sectional and could not adequately assess the temporality of the relationship between BV
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and CT and/or NG.(Allsworth & Peipert, 2011; Bautista et al., 2017; Ness et al., 2005;
Wiesenfeld, Hillier, Krohn, Landers, & Sweet, 2003)
Wiesenfeld and colleagues conducted a cross sectional study, which included
predominantly African-American (59%) women, and concluded that women with BV had
four times increased odds to test positive for NG infection and 3.4 times increased odds
to test positive for CT than women without BV.(Wiesenfeld et al., 2003) They
hypothesized that hydrogen peroxide (H2O2) -producing lactobacilli was an essential
defense against CT/NG infection. Bautista et al. conducted a population based, nested
case-control study among US army women and determined that antecedent BV was
associated with an increased risk of NG (Adjusted incidence rate ratio: 2.42; 95%
Confidence Interval [CI]: 2.27-2.57) and CT infections (Adjusted incidence rate ratio:
1.51; 95% CI: 1.47-1.55).(Bautista et al., 2017) They further concluded that there was a
monotonic dose-response relationship between BV and CT and/or NG
infections.(Bautista et al., 2017) Though the relationship between BV and CT and/or NG
infections have been explored in the literature, many studies have not assessed the
longitudinal effect of persistent and episodic BV on the acquisition of CT/NG infection.
Due to a lack of effective treatment, multiple episodes of BV are common in the
same women over a period of time.(Brotman et al., 2007) Furthermore, the distinction
between BV reinfection and relapse is unclear, since the etiopathogenesis of BV remains
unknown.(Brotman et al., 2007) Episodic BV may be due to ineffective antibiotic
treatment, which fails to resolve a persistent BV infection.(Bradshaw et al., 2006;
Coudray & Madhivanan, 2020) Persistent BV is diagnosed among women with BV at
consecutive visits.(Lennard et al., 2018) Persistent BV infection is associated with genital
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inflammation and biofilm formation.(Lennard et al., 2018) These biofilms enhance
microbial attachments to the genital epithelium and block antimicrobial action resulting
in persistent BV.(Lennard et al., 2018) Though the literature has examined the
association between BV and incident STIs, this has historically been assessed based on a
singular episode of BV. In this study, we sought to determine whether women with
persistent BV were more likely to acquire a CT/NG infection compared to women with
episodic BV in a population of African American women.

Methods
Study Design
Our study was a secondary analysis of previously collected data from a
randomized clinical trial (RCT). A detailed account of the RCT study procedures is
described elsewhere.(Schwebke et al., 2016) Briefly, the RCT aimed to investigate the
effect of home screening and treatment of asymptomatic BV to reduce the incidence of
CT and NG infections. This US-based study recruited reproductive age women (15-25
years) with asymptomatic BV from clinical research sites, STI and obstetrics/gynecology
clinics from five states (Maryland, North Carolina, Pennsylvania, California, and
Alabama). Women were eligible for the RCT if they had asymptomatic BV and
considered high-risk for STIs. Eligible women were randomized to a treatment or control
arm. Women assigned to the treatment arm received oral metronidazole (500mg, twice a
day for seven days) at enrollment. According to the Centers for Disease Control and
Prevention (CDC) guidelines (standard of care), women in the control arm did not receive
treatment for asymptomatic BV.(Workowski & Berman, 2010) All women could receive
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treatment from healthcare providers, outside the parameters of the study, if necessary.
Women received home testing kits every two months to self-collect vaginal swabs to test
for BV. Every four months, additional swabs were included to test for CT and NG. For
every BV positive home testing kit, only women assigned to the treatment arm received
oral metronidazole (500mg, twice a day for seven days). The presence or absence of BV
symptoms was not assessed after baseline. Participants were followed for 12 months. The
current study only examined women assigned to the control arm. We aimed to compare
the effect of persistent versus episodic cases of BV on STI acquisition.

Measures
BV was assessed microbiologically using NS at every time point. A NS of 0-3
was considered as ‘no BV’, 4-6 as ‘intermediate flora’, and 7-10 indicative of
‘BV’.(Mohammadzadeh, Dolatian, Jorjani, & Alavi Majd, 2014) NS at two months, four
months and six months were combined to classify women as persistent BV, episodic BV
or no BV. Women with NS of 7-10 at months two, four and six were classified as
persistent BV. Women with NS 0-6 at month two, four and six were defined as no BV.
All other cases were classified as episodic BV. A BV status variable was created to
include the following categories: persistent BV, episodic BV and no BV.
A baseline questionnaire was administered, which examined sociodemographic
factors such as age, race, and the highest level of education. All women completed a selfadministered questionnaire at each visit, which evaluated factors such as contraceptive
methods and sexual risk behaviors. The use of birth control pills, birth control patch,
Nuva-ring, condoms, spermicide cream, Depo-Provera shot, Intra-uterine device (IUD)
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were assessed at each visit. These birth control methods were further categorized as
barrier methods (yes/no) where the use of condoms was considered as a barrier method
and all other forms of birth control were not. The number of different sex partners (any
sexual encounter), number of oral sex partners (receptive), number of unprotected anal
sex partners, number of unprotected vaginal sex partners, women who have sex with
women and new sex partners (partners they did not have sex with previously) were
evaluated. Sexual behavior was assessed as yes/no. Responses for all variables were
assessed for month two, four and six. Outcomes were classified as ‘yes’ if participants
responded yes at any time point (month two, four or six) and no if they responded ‘no’ at
all timepoints (month two, four or six). Vaginal swabs were tested for chlamydia and
gonorrhea by the BD ProbeTec Amplified DNA AssayTM (Becton-Dickson, Inc. Sparks,
MD) according to manufacturer instruction.

Sample
There were 1,365 women included in the original RCT. A subset of 1,160 women
agreed for their data to be used in future research. From this sample of 1,160 women,
only African American women were included (N= 976, 84.1%) due to their increased risk
of both BV and STIs as well as the need for further research among this population.
Follow-up data were available for 872 (89.3%) of these women. Women in the treatment
arm (N=444; 50.9%) were then excluded to remove the effect of treatment for BV.
Consequently, 428 women (59.3%) were included in the final analysis.
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Statistical Analysis
The absence or presence of CT/NG at month eight was categorized as a single
outcome, “STI” (yes/no). Age was the only continuous variable assessed and then
categorized for analysis into two levels (≤21 years and >21 years). Descriptive analyses
were conducted using either Chi-Squared or Fisher’s Exact Test, as appropriate, to
compare women with and without any STIs. Differences among BV status groups were
also determined.
The bivariate relationship between all demographic, contraceptive methods and
sexual risk behavior variables and incident STI were examined using the Binary Logistic
Regression Model. Variables with p-value <0.20 were included in the final model. Twoway interactions among BV status, contraceptive methods and sexual risk behavior were
tested. The final Logistic Regression Model included age, education, women who have
sex with women and BV status. None of the model assumptions were violated.
Multicollinearity was assessed using Cramer’s V and Phi Coefficient as appropriate. The
R Project for Statistical Computing version 3.5.1 (Vienna, Austria) was used for the
cleaning and analysis of data.

Results
Participant Characteristics
All women included in this study were African American. Of these, 239 women
(55.8%) were ≤21 years. The mean age of the women was 21.3 (Standard Deviation
(SD): ±2.1) years. Most women in the study completed more than a high school diploma
or GED (50.9%). Additionally, 141 women (32.9%) completed up to high school and 69
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women (16.1%) did not complete high school. Most women (82.2%) used barrier
contraception methods (i.e., condoms) and engaged in sexual behavior that might put
them at risk for STI: 402 (93.9%) women had one or more sex partners, 397 (92.8%)
women had one or more oral sex partners (receptive), 267 (62.4%) women had
unprotected anal sex, 400 (93.5%) women had unprotected vaginal sex with two or more
partners, 203 (47.4%) women had sex with other women, and 238 (55.6%) women had
new sex partners. There were 179 women (41.8%; 95% CI: 37.1%-46.7%) with persistent
BV, 204 women (47.7%; 95% CI: 42.8%-52.5%) with episodic BV, and 45 women
(10.5%; 95% CI: 7.8%-13.8%) with no BV after baseline. About 8.6% (95%CI: 6.2%11.7%) of women were diagnosed with an incident case of STI, either CT or NG, within
eight months. There were 28 (75.7%; 95% CI: 58.8%-88.2%) cases of CT only, 2 (5.4%;
95% CI: 0.6%-18.2%) cases of NG only, and 7 (18.9%; 95% CI: 7.9%-35.2%) women
were coinfected with CT and NG. None of the exposure variables were significantly
associated with BV status. Participant characteristics stratified by STI presence and BV
status are detailed in tables one and two, respectively.

Factors Associated with STI Incidence
Descriptive analyses indicated that STI incidence after eight months was
significantly associated with age (p=0.04), education (p<0.01), and BV status (p=0.02).
These variables were then included in the final binary logistic regression model.
Additionally, sexual activity with other women (p=0.09) was also included in the final
model since the p-value was <0.20. There were no STIs diagnosed at eight months among
women who had no BV. Thus, in the final model, women with persistent BV were
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compared to women with episodic BV. The unadjusted logistic regression model
indicated women older than 21 years (Crude Odds Ratio (OR): 0.44; 95%CI: 0.20-0.90),
who had completed at least high school (OR: 0.36; 95%CI: 0.15-0.86) or more than high
school (OR: 0.27; 95% CI: 0.12-0.63) had decreased odds of an incident STI.
Additionally, when compared to women with episodic BV, women with persistent BV
had decreased odds (OR: 0.59; 95% CI: 0.28-1.17) of acquiring an STI at eight months,
although this was not statistically significant. Similarly, women who had sex with women
had 1.93 increased (95% CI: 0.97-3.94) odds of developing an STI within eight months.
The final logistic regression model after adjusting for age, education, sexual activity with
other women and BV status, indicated that persistent BV was not associated with STI
acquisition when compared to episodic BV. Furthermore, it should be noted there were
no STIs among women classified as no BV. Additionally, women who had sex with
women (adjOR: 1.98; 95% CI: 0.97-4.17) had increased odds of developing an STI
compared to women who did not have sex with other women. This finding approached
marginal significance (p=0.06). Education was also associated with decreasing the odds
of STI acquisition, as women with high school education (adjOR: 0.38; 95% CI: 0.150.92) and more than high school education (adjOR: 0.31; 95% CI: 0.13-0.73) had lower
odds of acquiring incident STI compared to women with less than high school education.
Women aged 21 years and older had decreased odds of STI acquisition (adjOR: 0.47;
95% CI: 0.21-1.00). This finding approached marginal significance (p=0.06). Education
was the only significant predictor of STI acquisition in the final model. All interaction
terms were not statistically significant.
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Discussion
We examined the relationship between episodic and persistent BV with the
acquisition of CT/NG in a longitudinal study. BV status was associated with the
acquisition of STIs (p=0.02) in the bivariate analysis using Fisher’s Exact test. The
association between BV and CT/NG infection has been adequately documented in the
literature.(Bautista et al., 2016; Bautista et al., 2017; Ness et al., 2005) The findings of
the logistic regression models revealed that women with persistent BV had decreased
odds of acquiring CT and/or NG compared to women with episodic BV. We speculate
that it is possible women with persistent BV would most likely exhibit symptoms
associated with BV, such as vaginal discharge and foul odor. This may reduce the
likelihood of these women engaging in unprotected sex, thus reducing their odds of
acquiring an STI. However, we cannot confirm this hypothesis as the presence or absence
of symptoms was not assessed after baseline in the parent study. We would further like to
emphasize that this finding did not yield statistically significant results in the regression
model, and the magnitude of the association between BV status and STI acquisition could
not be determined.
Though the association between BV status and STI acquisition was not significant
in the regression model, our descriptive analyses showed a significant association.
Women without BV did not acquire CT and/or NG. Previous studies have suggested that
the relationship between persistent and episodic cases of BV and STI acquisition may be
due to the lack of the H2O2-producing lactobacilli bacteria, and the corresponding host
defense effect, associated with BV.(Wiesenfeld et al., 2003) Additionally, it is possible
that the production of mucin degrading enzymes may also contribute to STI
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susceptibility.(Allsworth & Peipert, 2011) We postulate that this effect may be
exaggerated in women who experience episodic or persistent BV further disrupting the
vaginal ecosystem. Though the etiology for this phenomenon remains unclear, the
clinical implications of these findings are still pertinent. Due to the high likelihood of
episodic and persistent BV, the mechanism by which BV recurs or persists and
subsequent STI infection needs to be further elucidated.
Women who had sex with women compared with women who did not have sex
with women (adjOR: 1.98; 95%CI: 0.97-4.17; p=0.06) had increased odds of acquisition
of CT and/or NG. This increased odds of STI acquisition may be due to vaginal sexual
activity with fingers, hands, and shared sex toys common among women who have sex
with women.(Singh, Fine, & Marrazzo, 2011) Additionally, it is possible that there was
infrequent use of barrier methods among this group to prevent STI transmission as most
women who report having sex with women do not believe that they are at increased risk
of STIs from their female sex partners.(Marrazzo, Coffey, & Bingham, 2005; Singh et al.,
2011) Furthermore, literature shows that women who have sex with women are more
likely to select high-risk sex partners.(Koh, Gómez, Shade, & Rowley, 2005; Lemp et al.,
1995) These women may also engage in unprotected sex with men.(Singh et al., 2011)
We did not assess exclusive sexual activity with women and thus cannot confirm this
hypothesis. Finally, we found that higher levels of education significantly decreased the
risk of STIs. This finding was consistent with the published literature.(Annang,
Walsemann, Maitra, & Kerr, 2010) Annang et al. determined that there was an inverse
association between the level of education and STI diagnosis.(Annang et al., 2010) This
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may be a result of increased awareness and reduced engagement in sexual behavior that
might increase their risk for STI.
Despite our findings, our study was subject to a few limitations. First, our final
models compared between women categorized as persistent and episodic BV. We could
not include women without BV into the model since none acquired an STI. Additionally,
though our sample was restricted to the control group, women could see their healthcare
providers for any symptom development, but these data were not captured. Finally, we
did not include partner testing for CT and NG; therefore, the effect of this on CT or NG
acquisition could not be assessed. However, our study is inherently strengthened by its
longitudinal assessment of STI acquisition. Furthermore, we implemented unique
definitions of persistent and episodic BV. Finally, we explored the lesser examined area
of research on BV and looked at the effect of multiple episodes of BV on STI acquisition.
Our study highlights the increased risk of STI acquisition among women with
persistent and episodic BV as no women without BV acquired an STI. These findings
demonstrate the serious effects associated with disruptions in the vaginal ecosystem
caused by persistent and episodic BV. Maintenance of a Lactobacillus dominant,
inflammation free vaginal ecosystem is essential to prevent the acquisition of STIs.
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Tables
Table 1: Characteristics associated with incident STIa Infection after eight months
Characteristics

Categories

N (%)

Any STIa (N=428)
Yes
No
(37; 8.6%)
(391; 91.4%)

≤21 years
>21 years

239 (55.8%)
189 (44.2%)

27 (73.0%)
10 (27.0%)

212 (54.2%)
179 (45.8%)

No HS
HS
More than HS

69 (16.1%)
141 (32.9%)
218 (50.9%)

13 (35.1%)
11 (29.7%)
13 (35.1%)

56 (14.3%)
130 (33.2%)
205 (52.4%)

No
Yes

76 (17.8%)
352 (82.2%)

8 (21.6%)
29 (78.4%)

68 (17.4%)
323 (75.5%)

No
Yes

26 (6.1%)
402 (93.9%)

4 (10.8%)
33 (89.2%)

22 (5.6%)
369 (94.4%)

Age

p-value

0.04

Education

<0.01

Barrier Methodsb

0.68

Different Sex Partnersc

0.27

Oral Sex Partnersc,d

0.50
No
Yes

Unprotected Anal Sex Partnersc
No
Yes

31 (7.2%)
397 (92.8%)

1 (2.7%)
36 (97.3%)

30 (7.7%)
361 (92.3%)
0.22

161 (37.6%)
267 (62.4%)

10 (37.0%)
27 (73.0%)
76

151 (38.6%)
240 (61.4%)

Unprotected Vaginal Sex Partnersc
No
Yes

28 (6.5%)
400 (93.5%)

1 (2.7%)
36 (97.3%)

27 (6.9%)
364 (93.1%)

Sexual Activity with Other Womenc
No
Yes

225 (52.6%)
203 (47.4%)

14 (37.8%)
23 (62.2%)

211 (54.0%)
180 (46.0%)

190 (44.4%)
238 (55.6%)

15 (40.5%)
22 (59.5%)

175 (44.8%)
216 (55.2%)

0.50

0.09

New Sex Partnersc,e

0.75
No
Yes

BV Statusf

0.02
Persistent BV
179 (41.8%)
13 (35.1%)
166 (42.5%)
Episodic BV
204 (47.7%)
24 (64.9%)
180 (46.0%)
No BV
45 (10.5%
0 (0.0%)
45 (11.5%)
a
Incident Chlamydia trachomatis (CT) or Neisseria gonorrhoeae (NG) infection
b
Used condoms at either month two, four or six
c
Responded yes at either month two, four or six
d
Receptive oral sex
e
Partners they did not have sex with previously
f
BV status- Women with NS:0-6 at baseline, two months and four months were classed as no BV. Women with NS:7-10 at
baseline, two months and fourth months were classified as persistent BV. All other cases were defined as episodic BV.
HS- High school
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Table 2: Factors Associated with BV Status (N=428)
Characteristics

Categories

N (%)

BV Statusa (N=428)
Persistent BV
Episodic BV
(179; 41.8%)
(204; 47.7%)

No BV
(45; 10.5%)

p-value

Age

0.49
≤21 years
>21 years

239 (55.8)
189 (44.2)

95 (53.1%)
84 (46.9%)

120 (58.8%)
84 (41.2%)

24 (53.3%)
21 (46.7%)

No HS
HS
More than HS

69 (16.1%)
141 (32.9%)
218 (50.9%)

31 (17.3%)
60 (33.5%)
88 (49.2%)

31 (15.2%)
70 (34.3%)
103 (50.5%)

7 (15.6%)
11 (24.4%)
27 (60.0%)

No
Yes

76 (17.8%)
352 (82.2%

31 (17.3%)
148 (82.7%)

34 (16.7%)
170 (83.3%)

11 (24.4%)
34 (75.6%)

26 (6.1%)
402 (93.9%)

8 (4.5%)
171 (96.5%)

14 (6.9%)
190 (93.1%)

4 (8.9%)
41 (91.1%)

31 (7.2%)
397 (92.8%)

14 (7.8%)
165 (92.2%)

13 (6.4%)
191 (93.6%)

4 (8.9%)
41 (91.1%)

Education

0.69

Barrier Methodsb

0.46

Different Sex Partnersc
No
Yes

0.41

Oral Sex Partnersc,d

0.71
No
Yes

Unprotected Anal Sex Partnersc
No
Yes

0.22
161 (37.6%)
267 (62.4%)

74 (41.3%)
105 (58.7%)

Unprotected Vaginal Sex Partnersc

68 (33.3%)
136 (66.7%)

19 (42.2%)
26 (57.8%)
1.00
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No
Yes
Sexual Activity with Other Womenc,e
No
Yes

28 (6.5%)
400 (93.5%)

12 (6.7%)
167 (93.3%)

12 (5.9%)
192 (94.1)

4 (8.9%)
41 (91.1%)

225 (52.6%)
203 (47.4%)

105 (58.7%)
74 (41.3%)

99 (48.5%)
105 (51.5%)

21 (46.7%)
24 (53.3%)

0.10

New Sex Partnersc

0.53
No
190 (44.4%)
74 (41.3%)
94 (46.1%)
22 (48.9%)
Yes
238 (55.6%)
105 (58.7%)
110 (53.9%)
23 (51.1%)
a
BV status- Women with NS:0-6 at baseline, two months and four months were classed as no BV. Women with NS:7-10 at
baseline, two months and fourth months were classified as persistent BV. All other cases were defined as episodic BV.
b
Used condoms at either month two, four or six
c
Responded yes at either month two, four or six
d
Receptive oral sex
e
Partner they did not have sex with previously
HS- High school

79

Table 3: Factors Associated with Sexually Transmitted Infection Diagnosis among Participants (N=383)
Characteristics

Categories

Unadjusted
Odds Ratio
(95%CI)

p-value

Adjusted
Odds Ratio
(95%CI)

p-value

Age
≤21 years
>21 years

Ref
0.44 (0.20-0.90)

No HS
HS
More than HS

Ref
0.36 (0.15-0.86)
0.27 (0.12-0.63)

0.03

Ref
0.47 (0.21-1.00)

0.06

0.02
<0.01

Ref
0.38 (0.15-0.92)
0.31 (0.13-0.73)

0.03
0.01

Education

Sexual Activity with Other Womena
Yes
No

1.93 (0.97-3.94)
Ref

0.06

1.98 (0.97-4.17)
Ref

0.06

0.59 (0.28-1.17)
Ref

0.14

0.62 (0.29-1.28)
Ref

0.21

BV Statusb
Persistent BV
Episodic BV
a

Responded yes at either month two, four or six
BV status- Women with NS:7-10 at baseline, two months and fourth months were classified as persistent BV. Women with a
NS:7-10 at either month two, four or six were defined as episodic BV. Women with NS:0-6 at baseline, two months and four
months were classed as no BV and were not included in the final logistic regression model.
HS- High school
b
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CONCLUSIONS
Despite the many years of research on BV, the mechanisms by which BV recurs
and persists remain unknown. Our literature search highlighted that though BV treatment
is effective short term, the long-term recurrence rates are high. It further illustrated what
little is known about the etiology of single cases of BV, recurrent BV and persistent BV.
To our knowledge this is the first study to implement LCA techniques to examine the
patterns of BV incidence over time. We concluded that over a twelve-month period most
women were classed as persistent or recurrent BV despite treatment, further emphasizing
the poor efficacy of metronidazole treatment. Treatment increased the odds of recurrent
cases of BV.
Additionally, it is also the first study to compare the risk of STI acquisition
among women with persistent and episodic BV. Women who had sex with women were
more likely to have a recurrent or persistent case of BV. Our final study demonstrated
that women without BV did not acquire an STI. Our findings suggest that multiple
episodes of BV are common among women of reproductive age despite treatment with
metronidazole. Additionally, women with multiple episodes of BV were more likely to
acquire an STI in bivariate analyses.
Our findings collectively highlight the effects of poor BV treatment and the
increased risk of adverse sequalae among women with multiple episodes of BV. Further
research should examine the longitudinal microbial changes among women with
persistent, recurrent and episodic BV. Transition models should be used to examine the
risk factors of multiple cases of BV and the protective factors of women able to maintain
a healthy vaginal microbiota. Additionally, the host immune response among women
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with BV should be investigated to elucidate potential mechanisms by which the vaginal
microenvironment could be normalized. These findings may lead to more effective
treatment to reduce persistence and recurrence of BV.
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